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General introduction
The graft survival after renal transplantation has significantly improved during the past 
decades. The short-term results are mainly responsible for this improvement, since the long-
term graft attrition rate has only slightly decreased and remains approximately 4% per year (1). 
The definition of long-term graft attrition is not univocal, but it usually denotes patient death or 
allograft failure necessitating renal replacement therapy from the fifth year post transplantation 
(2). Various immunological and non-immunological processes can be responsible for long-
term graft attrition as summarized in Table 1 (3). Frequently, the late allograft loss cannot be 
attributed to a single obvious cause but is the consequence of multiple processes leading 
to cumulative injury. Some causes of long-term graft loss can be tackled by optimizing 
the immunosuppressive therapy in order to reduce the rate of acute rejections, prevent 
nephrotoxicity, obtain more stable blood concentrations, and improve adherence.
Immunosuppressive therapy after renal transplantation
The initial immunosuppressive therapy after renal transplantation usually consists of a 
combination of 3 drugs: a calcineurin inhibitor or mammalian target of rapamycin (mTOR) 
inhibitor, an antiproliferative agent, and corticosteroids. Most transplant recipients also receive 
induction therapy with depleting or non-depleting anti-T cell agents. These immunosuppressive 
drugs impede different steps in the immune response to prevent graft rejection. The availability 
of newer and more effective drugs has improved the outcome of renal transplantation, 
but increases the occurrence of adverse effects such as susceptibility to infections, risk of 
malignancies, and drug toxicity.
The optimal immunosuppressive regimen meets four important requirements. First, 
the regimen is effective in preventing graft rejection. Second, the toxicity profile of the 
immunosuppressive drugs is acceptable. Third, adherence to the regimen is easily achievable. 
Finally, the costs of the immunosuppressive regimen are low.
In the next paragraphs, the mechanisms of action and adverse effects of currently used 
immunosuppressive drugs are briefly described. This is followed by a discussion on how to 
optimize the use of two of these drugs, tacrolimus and mycophenolate mofetil (MMF).
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Table 1 
Causes and risks of graft failure (3)
Non-immune donor risks Deceased donor kidney, donation after circulatory death
Donor age above 60 years, female donor sex, donor vascular 
disease or vascular comorbidity
Ischaemia-reperfusion injury and long ischaemia times
Delayed graft function
Non-immune recipient risks and 
causes
Female sex, size mismatch, obesity
Ascending urinary tract infection and graft pyelonephritis
Transplant ureteric obstruction
Polyoma (BK) virus nephropathy
Calcineurin inhibitor nephrotoxicity
Recurrent renal disease or de novo glomerulonephritis
Hypertension, hyperlipidaemia, smoking, proteinuria
Pre-existing or post-transplantation diabetes
Alloimmune factors Child or adolescent recipient
Ethnicity with altered disposition of immunosuppressive agents
Variable concentration of medication
Recipient’s genetic trait for alloimmune and inflammatory  
response
Histoincompatibility, recipient presensitisation, and pre-existent 
donor specific antibodies
Acute rejection that is severe, steroid-resistant, vascular, antibody-
mediated, or occurring late after transplantation
Subclinical rejection, chronic T-cell mediated rejection, late de 
novo anti-HLA antibody formation, chronic antibody-mediated 
rejection with transplant glomerulopathy
Non-adherence to immunosuppressive drugs
Corticosteroids
Corticosteroids are used in renal transplantation as induction and maintenance therapy and 
to treat acute rejections. Corticosteroids act by binding to the glucocorticoid receptor and 
this complex subsequently binds to the nuclear DNA where it regulates the expression of 
genes that control the immune response and inflammation (4). The use of corticosteroids is 
associated with a broad range of toxicities like skin fragility, bodyweight gain, osteoporosis, 
hypertension, dyslipidaemia, and hyperglycaemia (4).
 1
General Introduction and Outline of this Thesis
12
Calcineurin inhibitors
One of the calcineurin inhibitors, tacrolimus or cyclosporine, usually forms the cornerstone 
of the immunosuppressive therapy after renal transplantation. These drugs inhibit the 
phosphatase activity of calcineurin after binding to FK506-binding protein (FK506-BP) or 
cyclophilin. Calcineurin dephosphorylates the nuclear factor of activated T cells (NFAT), 
allowing this transcription factor to enter the nucleus and to bind to the promotor of several 
cytokine genes. The blockade of this process by calcineurin inhibitors impairs T cell activation 
and proliferation. In several clinical trials it has been demonstrated that tacrolimus is more 
effective than cyclosporine in the prevention of acute rejection (5).
Tacrolimus was developed as an oral twice-daily formulation, in 2007 a prolonged-release 
once-daily formulation was introduced. Prolonged-release tacrolimus was developed 
by adding a combination of ethylcellulose, hypromellose and lactose monohydrate to 
tacrolimus (6). Ethylcellulose changes drug release by controlling water penetration and 
hypromellose affects drug release by forming a protective polymer gel layer around the 
drug. Consequently, tacrolimus is slowly released from the once-daily formulation along 
the gastrointestinal tract. Recently, a novel prolonged-release formulation LCP-tacrolimus 
was introduced. This formulation has a drug delivery technology, which improved the oral 
bioavailability (7).
Adverse effects effects of cyclosporine include hypertension, dyslipidaemia, hirsutism, 
and nephrotoxicity (8). The main side effects of tacrolimus are diabetes mellitus, diarrhea, 
nephrotoxicity, and various neurologic disorders (9). 
mTOR inhibitors
mTOR inhibitors, such as sirolimus and everolimus, form complexes with FK-binding protein 
12 which binds and thereby inhibits mTORC1. Consequently, mTOR inhibitors inhibit the 
proliferation of antigen-activated T cells by blocking their growth factor signaling pathways 
and arresting the cell cycle. The main advantage of mTOR inhibitors compared to calcineurin 
inhibitors is reduced nephrotoxicity. However, mTOR inhibitors are also associated with a 
variety of side effects like proteinuria, hyperlipidaemia, and diabetes mellitus (10).
Anti-proliferative agents
To this group belong MMF, enteric coated mycophenolic acid (EC-MPS), and azathioprine. 
MMF and EC-MPS are prodrugs of mycophenolic acid (MPA), which inhibits a key enzyme, 
inosine monophosphate hydrogenase (IMPDH), in the de novo purine synthesis. Inhibition 
of IMPDH leads to arrest of T and B cell proliferation, suppression of antibody formation and 
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reduced recruitment of leucocytes to sites of inflammation. Adverse effects of mycophenolate 
compounds include anemia, leucopenia, and diarrhea (11).
Azathioprine is a purine analogue that antagonizes endogenous purines. Azathioprine is 
the prodrug of 6-mercaptopurine, which is converted to 6-thioguanine nucleotides. The 
latter inhibits normal nucleotide and protein synthesis, which ultimately results in inhibition 
of lymphocyte proliferation. The most relevant side effects of azathioprine are nodular 
regenerative hyperplasia of the liver, leucopenia, and thrombocytopenia.
Optimizing the use of mycophenolate mofetil and tacrolimus
Nowadays MMF and tacrolimus are in most renal transplant centers the anti-proliferative agent 
and calcineurin inhibitor of choice due to their balance between efficacy and side effects, (6, 
12). Therefore, the emphasis in this thesis is on the optimal use of these immunosuppressive 
agents. Optimization of the immunosuppressive therapy can be achieved by increasing the 
efficacy, reducing the adverse effects and improving the adherence.
The efficacy of MMF will improve if the exposure to its active metabolite MPA is adequate since 
this decreases the rate of acute rejection in renal transplant patients (13-16). However, several 
investigators showed that the frequently prescribed combination of proton pump inhibitors 
(PPIs) and MMF reduces the exposure to MPA (17, 18). Whether this leads to more acute 
rejections is unknown.
A second option to optimize the immunosuppressive regimen is to reduce tacrolimus 
nephrotoxicity. Therapeutic drug monitoring (TDM), which allows individualization of the dose 
based on concentration measurements, is commonly applied by measuring trough levels. 
The aim is to prevent insufficient protection against rejection due to underexposure as well as 
nephrotoxicity as a consequence of overexposure. TDM of tacrolimus could be improved and 
simplified in order to achieve these goals. Moreover, the current practice of measuring trough 
levels might not suffice in circumstances, which affect the pharmacokinetics of tacrolimus such 
as diarrhea.
Thirdly, a better adherence to the immunosuppressive regimen with more stable blood levels 
of the immunosuppressive agents might be achieved by increasing the treatment satisfaction. 
Simplifying of the medication regimen could be an approach to improve the treatment 
satisfaction and thereby also the adherence.
 1
General Introduction and Outline of this Thesis
14
Since this thesis focuses on these three strategies to improve outcome after renal 
transplantation, the next section of this chapter will provide more background information on 
the respective topics.
Mycophenolate mofetil and proton pump inhibitors
After oral administration, MMF is rapidly absorbed and undergoes extensive presystemic de-
esterification to MPA. The MPA peak concentration is reached within 1-2 hours after ingestion of 
MMF. MPA is mainly found in the plasma where it binds extensively to serum albumin (19, 20). 
MPA is metabolized in the liver by glucoronyl transferases to mycophenolic acid glucuronide, 
which is partly excreted into bile and undergoes enterohepatic recirculation after conversion to 
MPA in the colon.
PPIs are frequently prescribed post transplantation as prophylaxis for peptic ulcer disease, 
which is common and can cause significant morbidity and mortality (21). During the last years, 
a series of studies have reported that PPI therapy decreases MPA exposure in renal transplant 
patients, heart transplant patients, patients with autoimmune diseases, and healthy volunteers 
(18, 22-25). Concomitant use of pantoprazole 40 mg resulted in 34-37% lower exposure 
to MPA (17, 18). PPIs can raise the gastric pH level above 4, which results in a decreased 
de-esterification of MMF and thereby a reduction of the MPA plasma concentration (26). The 
clinical relevance of this pharmacokinetic interaction between PPI and MMF is currently unclear.
Tacrolimus and therapeutic drug monitoring
The bioavailability after oral administration of tacrolimus is approximately 20% and exhibits a 
wide inter-individual variability ranging from 4% to 93% (27). Tacrolimus is rapidly absorbed 
with a peak concentration within 1 hour after the intake in most subjects, but this can be 
delayed till 6 hours depending on gut motility (27). The efflux ABCB1 pump, previously 
known as P-glycoprotein encoded by the adenosine triphosphate binding cassette subfamily 
B member 1 (ABCB1) gene, and CYP3A isoenzymes form a cooperative barrier against 
tacrolimus absorption in the intestine. The ABCB1 pump lowers the intracellular concentration 
of tacrolimus by pumping absorbed drug back into the intestinal lumen. The intracellular 
tacrolimus concentrations are kept within the linear range of the metabolizing capacity of 
the CYP3A enzymes, which modify the FK506 BP binding site (28). After tacrolimus has 
passed the intestinal wall and reached the portal vein, it is metabolized by hepatic CYP3A 
isoenzymes. The ABCB1 expression and the metabolic capacity of the CYP3A isoenzymes 
display a considerable inter-individual variability. In biopsies of the small intestine, the ABCB1 
expression showed a 2- to 8- fold variation (29). The main CYP3A isoenzymes that metabolize 
tacrolimus are CYP3A4 and CYP3A5. Several polymorhisms in the genes encoding these 
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enzymes add to the inter-individual variability in tacrolimus clearance. Expressers of the 
CYP3A5*1 allele clear tacrolimus approximately 2-fold faster than the non-expressers, who are 
homozygous for CYP3A5*3 (30). The frequency of CYP3A5*1 expression depends on ethnicity 
and is 5-15% in Caucasians, 15-35% in Asians and 45-73% in Africans (31). A polymorphism 
in a gene which encodes a protein that functions as an electron donor for CYP3A5, POR*28 
also affects tacrolimus dose requirements in expressers of CYP3A5 (32). Finally, CYP3A4*22 
polymorphisms also cause inter-patient variability in tacrolimus clearance (30, 33). In addition, 
comedication, hematocrit and albumin concentration, patient age and race, time after 
transplantation, and liver function can affect the pharmacokinetics of tacrolimus (9).
Because of the wide variability of the pharmacokinetics and the limited therapeutic index 
of tacrolimus, TDM is indicated. However, the relationship between tacrolimus whole 
blood concentrations and efficacy or toxicity has not yet been fully established. Only a few 
studies addressed the relation between tacrolimus concentrations and outcome after renal 
transplantation (34-42). These studies provided conflicting data and the interpretation is 
hampered by small sample sizes and the use of immunosuppressive regimens, that differ from 
the current gold standard. Therefore, the optimal limits of the therapeutic index are difficult to 
define.
The area under the concentration-time curve (AUC) is the best measure of drug exposure, but 
performing a full pharmacokinetic profile is hindered by logistic and financial drawbacks (43). 
Most transplant centers therefore use the trough concentration of tacrolimus to estimate the 
exposure. The correlation between trough concentration and the AUC is moderate to high (6, 
44-47). A better prediction of the AUC can be obtained by limited sampling strategies, which 
are based on multiple regression analysis or Bayesian estimation.
Tacrolimus and diarrhea
Diarrhea is a frequent adverse event in patients treated with tacrolimus and has an important 
impact on the pharmacokinetics of the drug (48). In patients experiencing severe diarrhea 
(more than 3 times a day loose stools), the exposure to tacrolimus can increase substantially 
which is also reflected in an elevation of the trough level (49). Diarrhea precedes the rise in 
tacrolimus blood levels, indicating that the diarrhea is the cause of the increase of tacrolimus 
exposure and not a consequence (49). The increase in tacrolimus exposure during severe 
diarrhea could have several causes. Firstly, the bioavailability of tacrolimus can be raised 
by reduced enzymatic activity of the CYP3A system and/or ABCB1 in enterocytes that are 
damaged by intestinal inflammation or infection (9, 48, 50). Secondly, due to a shortened 
ileal transit time during diarrhea, a higher amount of tacrolimus may be delivered to the 
 1
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colon, where lower metabolic activity of CYP3A could result in increased absorption (51). 
Observations supporting this theory were made in a renal transplant patient with a short bowel 
syndrome where target tacrolimus levels were achieved with a very low dose, and in pigs that 
showed an increase in tacrolimus levels after resection of the small intestine (52, 53). Additional 
explanations for an increased exposure to tacrolimus during diarrhea are hemoconcentration, 
reduced hepatic metabolism, and fasting (9).
Non-adherence
Non-adherence to medication is a serious health concern among renal transplant recipients. 
Review papers describe that the prevalence of non-adherence to immunosuppressive therapy 
is about 25% (54, 55). It has been estimated that non-adherence contributes to 20% of late 
acute rejection episodes and 16-36% of graft losses, with a seven-fold increased risk of graft 
loss in non-adherent as compared with adherent patients (54, 55). The percentage of renal 
transplant patients who are not adherent is higher than in recipients of other solid organ grafts, 
possibly because of the non vital nature of the renal graft (56). In addition, the adherence to the 
non-immunosuppressive treatment is lower than to immunosuppressive drug therapy (57, 58).
A complex medication regimen is one of the risk factors for non-adherence (59). Evidence from 
several fields of pharmacotherapy shows that simplification of the drug regimen leads to a 
better adherence (60-62).
Outline of this thesis
The studies presented in this thesis focus on the optimization of the immunosuppressive 
therapy in renal transplant recipients in order to improve long-term graft survival. 
Sound knowledge on the interaction between immunosuppressive drugs and gastrointestinal 
tract function will improve immunosuppressive therapy. Chapter 2 provides a detailed review 
of the various aspects of this complex interaction including the concomitant use of PPI and 
MMF and the effect of diarrhea on tacrolimus exposure.
The combined use of PPI and MMF might lead to more acute rejections because of inadequate 
exposure to the active metabolite of MMF. Chapter 3 describes the results of a retrospective 
study in which the effect of combining MMF with either a PPI or with a histamine 2 antagonist 
on the rate of acute rejection is compared. 
General Introduction and Outline of this Thesis
17
In patients with chronic and not reported mild diarrhea, unnoticed tacrolimus overexposure 
could cause nephrotoxicity. Chapter 4 describes whether hidden tacrolimus overexposure 
indeed occurs in these subjects.
Experts in the field concluded that the AUC of tacrolimus is the best marker of exposure (43). 
Practical and financial disadvantages of a full pharmacokinetic profile are avoided by the use 
of a limited sampling strategy. A limited sampling strategy for estimation of the exposure to 
prolonged-release tacrolimus is described in chapter 5.
In daily clinical practice, most centers measure trough levels to estimate exposure to 
tacrolimus. Prolonged-release tacrolimus is taken once a day in the morning and trough level 
measurement is usually performed the next morning just before drug ingestion. However, some 
ambulatory patients visit the outpatient clinic in the afternoon and delayed measurement of 
the tacrolimus trough level would be a convenient option for them. In chapter 6, the results 
are presented of delayed trough level measurement in patients who use prolonged-release 
tacrolimus.
A better treatment satisfaction might lead to better adherence to the immunosuppressive regimen. 
The treatment satisfaction might improve by using a simplified medication regimen, which enables 
patients to take their drugs at one or two convenient time points per day. In chapter 7 the effects of 
such a simplified medication regimen on treatment satisfaction are reported.
Chapter 8 contains a summary of the thesis with general discussion and future prospects
 1
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Abstract
Gastrointestinal (GI) discomfort is common after renal transplantation and can be caused by 
the use of various immunosuppressive drugs. GI complications affect the quality of life, lead 
to an impaired graft survival and an increased mortality. Moreover, diseases and disturbances 
of the GI tract can also affect the pharmacokinetics of immunosuppressive drugs. This review 
addresses the interaction between immunosuppressive agents and GI disorders.
The GI tract is involved in the metabolism of several immunosuppressive drugs. Calcineurin 
inhibitors, mTOR inhibitors, and corticosteroids are subject to metabolism by the intestinal 
cytochrome P450 (CYP3A) and by the drug efflux pump ABCB1. Mycophenolate is partly 
metabolized in the stomach and intestine and undergoes enterohepatic recirculation. Diseases 
and disturbances of the GI tract can lead to a modified exposure to immunosuppressive 
drugs. In the first and second part of this review, we focus on the role of the GI tract in the 
pharmacokinetics of the immunosuppressive drugs and how to adjust immunosuppressive 
therapy in patients with disorders of the GI tract like vomiting, need for a nasogastric feeding 
tube, gastroparesis, intestinal resection, and diarrhea. 
In the third part, we review the GI adverse effects of the various immunosuppressive drugs, 
with special attention for diarrhea and dyspepsia. 
Finally, we discuss the effects that drugs used for relief of GI complaints can have on the 
exposure to immunosuppressive agents.
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Introduction
The current practice in maintenance immunosuppressive therapy for renal allograft recipients 
is to make use of a combination of various drugs, which interfere with different steps of the 
immune response. These drugs are generally classified according to their mechanism of 
action: the calcineurin inhibitors (CNI) which consist of cyclosporine A (CsA) and tacrolimus, 
the mammalian target of rapamycin (mTOR) inhibitors to which sirolimus and everolimus 
belong, the antiproliferative drugs, which include mycophenolate and azathioprine (AZA), and 
corticosteroids (CS).
Several factors, including diet, co-administration of some drugs or herbs and genetic features 
affect the blood concentration of these immunosuppressive drugs. It is not always recognized 
that disorders of the gastrointestinal (GI) tract like vomiting or diarrhea can also contribute to 
a modified exposure to immunosuppressive drugs. Moreover, some drugs used to treat these 
conditions can interact with the immunosuppressive agents.
Furthermore, the use of immunosuppressive drugs is a frequent cause of GI complaints. GI 
adverse events occurred in more than 80% of patients who received a renal allograft (1, 2). 
The most commonly reported GI complaints are dyspepsia, abdominal pain, diarrhea, and 
constipation (2). GI complications, and particularly diarrhea, are associated with poor graft 
outcome and patient survival (3, 4). Bunnapradist et al. retrospectively analyzed more than 
42,000 renal allograft recipients and established that the risk for graft failure and patient death 
was more than double in patients with noninfectious diarrhea (3). In addition, GI complaints 
can have detrimental effects on quality of life. Ekberg et al. reported that patient-reported 
GI symptoms were associated with an impaired quality of life, with a relationship between 
the severity of symptoms and the reduction in quality of life (2). The negative effect of GI 
symptoms on quality of life might result in reduced compliance with the immunosuppressive 
regimen, which in turn is a risk factor for graft failure (5, 6). Notably, GI symptoms tend to be 
underestimated by physicians, partly because patients do not always report these complaints 
(1).
Knowledge on the effects of disorders of the GI tract on the pharmacokinetics of 
immunosuppressive drugs and on GI adverse effects of immunosuppressive drugs, is 
essential to assist the physician in prescribing the optimal immunosuppressive regimen. 
Therefore, we will firstly discuss the role of the GI tract in the pharmacokinetics of the major 
maintenance immunosuppressive drugs. Secondly, we will address the consequences of GI 
disorders on the pharmacokinetics of immunosuppressive drugs and provide some practical 
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recommendations how to adjust the treatment regimen in these circumstances. Thirdly, we 
will summarize the GI adverse effects of immunosuppressive drugs, and finally the effects of 
medical treatment of GI complaints on the pharmacokinetics of immunosuppressive agents will 
be highlighted. The hepatic metabolism of the immunosuppressive agents, the effect of liver 
disease on the pharmacokinetics and the hepatic adverse effects are beyond the scope of this 
review.
Normal intestinal absorption and metabolism of immunosuppressive drugs
Calcineurin inhibitors, mTor inhibitors and corticosteroids 
CsA and tacrolimus are available in different capsule formulations with their own 
pharmacokinetic characteristics. Three tacrolimus formulations are yet available: regular, 
prolonged-release and prolonged-release with an innovative drug delivery technology 
(LifeCycle Pharma, LCP). Due to different dissolution properties, prolonged-release  tacrolimus 
is released further along the GI tract and can therefore be taken once daily. LCP-tacrolimus is 
a prolonged-release tacrolimus with a higher bioavailability due its drug delivery technology 
(7). Two formulations of CsA are delivered in capsules: an oil based preparation and a micro-
emulsion. In this review, we will only address the micro-emulsion formulation of CsA which is 
predominantly prescribed because of a higher and more predictable oral bioavailability (8).
CNIs, mTOR inhibitors and CS are all metabolized primarily by members of the cytochrome 
P450 3A family: CYP3A4 and CYP3A5. They are also substrates of the drug efflux pump 
ABCB1, previously known as P-glycoprotein. This pump is the encoded product of the 
adenosine triphosphate binding cassette subfamily B member 1 (ABCB1) gene, also known 
as multidrug resistance (MDR) 1 gene. CYP3A enzymes and ABCB1 form a cooperative 
barrier against absorption of xenobiotics. Drugs are repeatedly taken up and pumped out of 
enterocytes by ABCB1 and the repeated exposure to CYP3A enzymes increases the probability 
of being metabolized. ABCB1 keeps intracellular drug concentrations within the linear range 
of the metabolizing capacity of the CYP3A enzymes (9). The CYP3A isoenzymes metabolize 
immunosuppressive drugs by hydroxylation and demethylation.
Several studies showed that differences in expression of CYP3A4, CYP3A5 and ABCB1 cause 
patient-to-patient variability in the absorption and intestinal metabolism of drugs. The rate of 
the CYP3A enzymatic activity varied about 5 times between individuals in a in vitro study (10). 
Other studies showed that the intestinal CYP3A concentrations equaled or exceeded hepatic 
levels in some subjects, while in others the intestinal CYP3A concentration was only 10-50% of 
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the liver capacity (11, 12). Finally, Lampen et al. established that the inter-individual differences 
in expression of ABCB1 varied more than 8-fold in small intestine biopsies (13). 
CYP3A4 is the predominant CYP3A isoform in the GI tract, with an increase in the expression 
from stomach to the jejunum and then a decrease in the ileum (14). The intestinal expression 
of CYP3A5 is only relevant in carriers of the CYP3A5*1 allele, and is especially present in 
stomach and ileum (11, 12). Expressers have a faster intestinal tacrolimus metabolism than 
non-expressers (15). A polymorphism in a gene which encodes a protein that functions as an 
electron donor for CYP3A5, POR*28 also affects tacrolimus dose requirements in expressers 
of CYP3A5 (16). However, its contribution to the intestinal tacrolimus metabolism has to be 
elucidated. The ABCB1 expression is equally distributed in stomach, jejunum and ileum (14). 
A number of characteristics concerning intestinal absorption and metabolism of the various 
immunosuppressive drugs are summarized in Table 1.
Antiproliferative agents
Currently, two mycophenolate compounds are available: mycophenolate mofetil  (MMF) and 
enteric coated mycophenolate sodium (EC-MPS). In both cases, mycophenolic acid (MPA) is 
the active drug moiety. After oral administration, MMF and EC-MPS are extensively hydrolyzed 
to MPA by esterases in the stomach, small intestine, blood, liver and other tissues. The oral 
bioavailability of MPA, subsequent to MMF administration, ranges from 80 % to 94% depending 
whether it is measured in healthy volunteers or in transplant patients (17). EC-MPS has an 
absolute MPA bioavailability of approximately 72% in stable renal transplant patients who 
are treated with CsA (18). However, a lower oral bioavailability is reported directly after renal 
transplantation, possibly because of poor postoperative absorption or GI metabolism (18). In 
vitro studies indicate that the enteric coating of EC-MPS remains largely intact at pH 5.0, as in 
the stomach, but the tablet is highly soluble in neutral pH conditions, as present in the intestine 
(18). The uridine diphosphate glucuronosyltransferases metabolize MPA in the liver, and to a 
lesser extent in the GI tract and the kidneys. The major metabolite is the pharmacologically 
inactive MPAG, which is excreted into bile. Biliary excretion of MPAG is followed by intestinal 
deconjugation by bacteria in the colon where after MPA can be reabsorbed. This results in an 
important enterohepatic recirculation of MPA/MPAG, which accounts for 10%-60% of the total 
MPA exposure and is reflected in a second peak in the MPA concentration-time curve 6-12 
hours after the ingestion of MMF (17). CsA inhibits the biliary excretion of MPAG and therefore 
also the enterohepatic recirculation (19, 20). Consequently, patients treated with CsA usually 
require a higher dose of MMF than patients not treated with CsA (21).
After absorption, approximately 90% of the prodrug AZA undergoes conversion to 
6-mercaptopurine (6-MP) (22). AZA is converted to 6-MP by sulfhydryl-containing compounds, 
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which are present in every mammalian cell. The oral bioavailability of 6-MP ranges from 27% 
to 83% (mean 47%) (23). In a study with healthy volunteers, AZA was administered at different 
locations in the GI tract via an oral tube to measure differences in bioavailability (24). The 
exposure to 6-MP was highest if AZA was administered in the jejunum and lowest if AZA was 
delivered in the cecum, indicating that the small bowel is important in absorption of AZA.
Consequences of gastrointestinal abnormalities and diseases on the  
exposure to immunosuppressive drugs
Vomiting
In general, vomiting reduces the absorption of immunosuppressive drugs, particularly if drugs 
have not already passed the stomach and duodenum. There are no data available which 
indicate how to deal with patients who are vomiting and are not able to take their tablets. If the 
pills appear to be complete in the vomit or patients throw up within 0.5 hour after the ingestion, 
it is typically recommended to take again the full dose, considering that gastric emptying 
is delayed in vomiting patients and none of the drugs reaches its maximum concentration 
within 0.5 hour in normal circumstances. If the absorption of the immunosuppressive drugs 
is still insufficient, it is common practice to administer higher than maintenance doses of CS 
intravenously to avoid underimmunosuppression. If complaints persist for more than 24 hours 
CNI is usually administered intravenously. Based on the bioavailability of tacrolimus, a dose 
conversion rate 4:1 is then recommended. The aim with a continuous intravenous infusion 
is to attain blood concentrations, which are 1.4 times higher than the target trough levels 
applied for regular oral use (25). CsA can also be administered intravenously, but there is still 
debate on whether it should be infused continuously or as boluses. For the conversion from 
oral to intravenous administration of CsA, a 3:1 dose ratio is recommended in solid organ 
transplantation based on the bioavailability of CsA (26). Nakamura et al. estimated that the 
target blood concentration of CsA during continuous intravenous administration has to be 2.55 
times higher than the trough level aimed at with oral administration to obtain sufficient exposure 
(25). Since these blood levels are difficult to achieve, it might be more appropriate to use 
intravenous administration in two boluses per day.
Although MMF can also be administered intravenously, it is often discontinued if patients suffer 
from vomiting. GI adverse effects of MMF, like vomiting and diarrhea are not avoided if patients 
receive MMF intravenously (27).
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AZA can be given intravenously in a reduced dosage accounting for the bioavailability of about 
50%. Sirolimus and everolimus are poorly soluble in water and can therefore only be given 
orally.
In patients who vomit but otherwise have a normal function of the GI tract, some drugs may 
also be administered rectally. Rectal administration of tacrolimus results in systemic exposure 
and might represent an alternative for oral administration (28). Additional research should 
establish the optimal dose and dosing frequency for rectal administration. In contrast, CsA 
cannot be administered rectally since it leads to negligible systemic exposure (29). Finally, 
CS may also be rectally administered since hydrocortisone as rectal suppository resulted in 
adequate systemic exposure (30).
Nasogastric feeding tube
Direct enteral feeding through a nasogastric tube is required for patients who cannot swallow, 
but have a normal GI tract like ventilated patients. Possible issues in these patients may 
concern administration of oral tablets through the tube and bioequivalence of available 
alternatives such as sublingual and rectal administration (see above).
As tacrolimus capsules cannot be crushed, a suspension is available for administration via 
a nasogastric feeding tube. However, the bioavailability of this oral suspension is reduced 
due to incomplete solubility or absorption (31). An alternative for administration of tacrolimus 
by nasogastric feeding tube might be to administer the drug sublingually. Goorhuis et al. 
compared tacrolimus trough levels after sublingual administration and administration by 
nasogastric tube in pediatric liver transplant patients during the first week after transplantation 
(32). Trough levels were comparable in both groups. Some investigators confirmed that 
sublingual administration of tacrolimus results in therapeutic blood levels (33-35). However, 
van de Plas et al. and Stifft et al. could not confirm these results and ascribe the findings in the 
other reports to swallowing saliva containing drug and subsequent enteral absorption (28, 36). 
CsA solution can be administered by nasogastric feeding tube in the same dose as taken 
in tablets. Adequate trough levels of CsA were obtained using this solution administered by 
nasogastric feeding tube (37). 
Sirolimus is available as a solution and everolimus as a dispersible tablet. A study with stable 
renal allograft patients who were converted from the liquid to tablet formulation of sirolimus, 
demonstrated near bioequivalence for the two formulations (38). 
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CS are available in a liquid formulation for administration via a nasogastric feeding tube. Its 
administered dose is equivalent to the dose in tablets.
MMF can be given in a suspension formulation via a nasogastric feeding tube (18). However, if 
the tip of the tube lays in the duodenum this can result in reduced de-esterification of MMF and 
decreased exposure to MPA. EC-MPS tablets should not be crushed or cut prior to ingestion 
to maintain the integrity of their enteric coating. Therefore, they are not suited for administration 
via a nasogastric feeding tube.
Finally, AZA cannot be given via a nasogastric feeding tube since the tablet cannot be crushed 
and a liquid formulation is not available.
Gastroparesis
Gastroparesis is a syndrome characterized by delayed gastric emptying in the absence 
of mechanical obstruction. Diabetes mellitus and previous surgery are common causes of 
gastroparesis, but it is idiopathic in a considerable number of cases (39). It predominantly 
manifests as early satiety, postprandial fullness, nausea, and weight loss. The time course of 
gastric emptying can affect the absorption of immunosuppressive agents. The bioavailability 
of CsA is markedly impaired by gastroparesis (40). Although the rate of tacrolimus absorption, 
reflected by the time to achieve maximum blood concentration, is delayed, total absorption and 
the exposure to tacrolimus are unaffected by gastroparesis (41). The effect on exposure to the 
other immunosuppressive agents has not been investigated.
Tacrolimus has a strong prokinetic effect on the GI tract via motilin receptors, like erytromycin, 
another macrolide, which is administered to accelerate gastric motility. In contrast, CsA does 
not possess motilin modulating properties but even appears to slow gastric emptying of 
solids (42). Tacrolimus is therefore the CNI of choice in patients with gastroparesis (43). Since 
mTOR inhibitors also have prokinetic properties, they might be an alternative to tacrolimus 
(44). AZA, mycophenolate and CS do not affect gastric emptying (42, 44). Both formulations 
of mycophenolate provided a comparable exposure to MPA in 15 patients with severe 
gastroparesis (45).
Intestinal resection
The absorption site of CNIs, mTOR inhibitors and CS is particularly located in the upper GI tract 
(duodenum and proximal jejunum) and the effect on blood concentrations is most pronounced 
if this part of the tract has been resected (46). Consequently, the absorption capacity is 
diminished after intestinal resection, but the pattern of the concentration-time curve of CNI is 
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similar to that in subjects with a normal GI tract (47). After a jejunoileal bypass, therapeutic 
blood concentrations can be achieved with an elevated dose of a CNI (48).
There are no data about the effect of intestinal resection on the absorption of mTOR inhibitors. 
As discussed previously, mycophenolate undergoes enterohepatic recirculation, which 
contributes approximately 40% to the area under the concentration time curve (18). Goransson 
et al. described a patient who had a dramatic fall in MPA concentration after an ileostomy (49). 
The exposure to oral CS has reported to be normal in patients who underwent intestinal 
resection, although concomitant hypoalbuminemia seems to reduce the exposure to CS (50). 
The effect of intestinal resection on the absorption of AZA is unknown.
In all patients with intestinal resection, more intensive pharmacokinetic monitoring of 
immunosuppressive drugs is recommended. Before transplantation, pharmacokinetic 
measurements after a single or multiple test doses can be performed to provide an estimation 
of an appropriate starting dose after transplantation. An alternative approach might be to use 
belatacept instead of a CNI since it is given intravenously and therefore adequate exposure is 
warranted.
Diarrhea
Severe diarrhea, defined as more than 3 loose stools daily, is the result of inflammation, 
infection, or malabsorption amongst other causes. It can have an important impact on the 
pharmacokinetics of tacrolimus, increasing the exposure. The enhancement of tacrolimus 
exposure during severe diarrhea can be explained by two mechanisms. Firstly, the oral 
bioavailability of tacrolimus is raised by diminished activity of the CYP3A system and of ABCB1 
in enterocytes, which are damaged by intestinal inflammation or infection (51). Secondly, a 
higher amount of tacrolimus may be delivered to the colon due to a shortened ileal transit time 
during diarrhea. In the colon, a lower metabolic activity of CYP3A could result in increased 
absorption (52). Therefore, it is recommended to monitor tacrolimus levels intensively during 
and shortly after an episode of diarrhea. Although CsA, mTOR inhibitors and CS are also 
substrates for CYP3A isoenzymes and ABCB1, increased exposure during diarrhea has not 
been described for these drugs. This suggests that for these drugs the intestinal metabolism 
contributes lesser to total drug clearance than in the case of tacrolimus (53). There are no 
reports about the effect of diarrhea on exposure to AZA and mycophenolate. 
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Gastrointestinal side effects of immunosuppressive drugs
GI adverse effects due to immunosuppressive drugs are commonly reported. However, 
establishing the profile of adverse effects of each drug is hampered by the fact that most 
patients use a combination of immunosuppressive agents. Moreover, it can be difficult to 
distinguish side effects from complaints due to the underlying renal disease. In the sections 
below and in Table 2, we summarize the reported GI adverse effects of each agent separately.
Tacrolimus
A meta-analysis of data from randomized trials, which compared tacrolimus to CsA revealed 
that GI adverse effects were more common in patients treated with tacrolimus than in those 
treated with CsA (54). Especially, the incidence of diarrhea was two times higher in tacrolimus-
treated patients (n=1343). Presumed mechanisms are activation of the intestinal motilin 
receptor (see above) and decreased levels of adenosine triphosphate in the enterocyt (55).
The meta-analysis also revealed that dyspepsia (relative risk 1.31; 95% confidence interval 
1.00-1.70) and vomiting  (relative risk 1.41; 95% confidence interval 1.05-1.89) were more 
common in tacrolimus than in CsA treated patients (n=980). Telkes et al. reported that renal 
allograft recipients receiving an immunosuppressive regimen consisting of tacrolimus, CS and 
MMF had the highest frequency of erosive lesions in the upper GI tract (24.4%) as compared 
to patients treated with CsA-CS-MMF (18.4%) or CsA-CS (15.9%) (56). However, only the use 
of MMF was an independent risk factor for upper GI complications and increased the risk of 
erosions by 1.8 fold (56). Logan et al. were also not able to demonstrate a difference in the 
incidence of upper GI complications between renal allograft recipients on tacrolimus and 
those on CsA (57). Finally, in some case reports it was suggested that tacrolimus induces 
pancreatitis, possibly related to higher tacrolimus levels (58-60).
Cyclosporine
Gingival hyperplasia is a well-known complication of the use of CsA and is seen in 8% of 
the renal transplant patients (61). ABCB1 polymorphism might be associated with gingival 
hyperplasia since the transporter is expressed in the endothelial layers of blood vessels in 
gingival tissue (62). Hyperplasia can be aggravated by concomitant use of calcium channel 
blockers and inflammatory processes due to dental plaque accumulation and other local 
factors (63, 64). Appropriate oral hygiene and cessation of the calcium channel blocker are the 
cornerstone in controlling the inflammatory component and reducing the severity of gingival 
overgrowth. If hyperplasia nonetheless persists, discontinuation of CsA and switch to another 
immunosuppressive agent should be pursued. Treatment with azithromycin may improve 
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gingival hyperplasia, but it increases the CsA levels due to inhibition of its metabolism and is 
thus not routinely recommended (65).
CsA slows the gastric emptying of solid food and therefore patients can suffer from dyspepsia 
and vomiting although these complaints are less frequent than in tacrolimus-treated patients 
(see above). 
Moreover, CsA may be able to induce acute pancreatitis. The incidence reported in renal 
transplant patients treated with CsA is approximately 3% (66, 67). The onset of pancreatitis was 
repeatedly associated with strikingly high plasma levels of CsA and the severity of an attack 
diminished if the dose was reduced or if the immunosuppressive regimen was changed (66). 
Diarrhea occurs frequently in CsA treated patients, but less often than in patients receiving 
tacrolimus. The incidence varies in different studies between 14-47% (55). The mechanism of 
CsA-induced diarrhea is unclear (55). As might be expected, constipation appears to be more 
frequent in patients treated with CsA than in those treated with tacrolimus (54). The relative 
risk on constipation in 980 renal transplant patients who used tacrolimus versus CsA was 0.83 
(95% confidence interval 0.69-0.99).
mTOR inhibitors
Oral aphthous ulcers were in different studies reported by 10-100% of the patients receiving 
sirolimus in different studies (68). Mahe et al. suggested that ulceration is caused by a 
direct toxic effect of sirolimus on the oral mucous membranes (68). Others suggest that the 
antiproliferative effect of sirolimus and the effect on growth factors might be responsible for the 
occurrence of mucosal ulcerations (69). The wide variability in the frequency of aphthous ulcers 
is attributable to various factors like the moment of introduction, the underlying circumstances, 
and the applied treatment protocols. A higher incidence and severity of aphthous lesions is 
reported after switching from CNI to sirolimus (68). Also lack of CS co-administration may 
increase the incidence of oral ulcers (70). Chronic fissure of the lips and chronic gingivitis 
were also common (20% and 11%, respectively) in patients treated with sirolimus (68). Mouth 
ulceration was not noted in a large trial with everolimus in renal transplant patients; however 14 
% of the liver transplant patients (n=240) reported mouth ulcerations (71).
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mTOR inhibitors can also provoke diarrhea. The manufacturer reports that the incidence of 
diarrhea with the use of sirolimus varies from 25% to 42% (72). A dose dependent increase 
in the frequency of diarrhea was found in a large clinical trial (73). A dosage increment of 2 
mg to 5 mg sirolimus nearly doubled the incidence of diarrhea. The mechanism of sirolimus 
associated diarrhea is not exactly known. Sirolimus alters intestinal function in rabbits by 
decreasing the jejunal uptake of certain fatty acids and by inducing intestinal atrophy, leading 
to lipid malabsorption (74). Furthermore, like tacrolimus, sirolimus has the chemical structure of 
a macrolide, of which the prokinetic effects may offer an alternative explanation for the diarrhea 
(75). The use of everolimus (1.5 and 3 mg) compared to MMF (2000 mg) was also associated 
with more reports of diarrhea in renal transplant patients (n=588) who used CS and CsA as 
concomitant treatment (23% versus 16%) (76).
Other reported adverse effects of mTOR inhibitors include abdominal pain, nausea, vomiting, 
dyspepsia, and notably also constipation. 
Mycophenolate
Especially diarrhea, but also nausea, vomiting, dyspepsia and anorexia are frequently 
encountered in patients using MMF. In three clinical trials where MMF was combined with CsA 
in renal transplant recipients, the incidence of diarrhea within the first year after transplantation 
ranged from 15.6% to 32.5% for a 2000 mg daily dose of MMF and from 15.6% to 37.3% for 
a 3 gram daily dose (77-79). The incidence of diarrhea in the control groups treated with AZA 
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Table 2 
GI adverse effects of various immunosuppressive agents
Oral ulcers
stomatitis
Gingival 
hyperplasia
Nausea 
vomiting
dyspepsia
Delayed 
gastric 
emptying
Pancreatitis Chronic 
diarrhea
Constipation
Tacrolimus + 0 ++ 0/+ 0/+ ++ +
Cyclosporine 0 + + + 0/+ + 0
mTOR 
inhibitors
++ 0 ++ 0 0/+ ++ ++
Corticosteroids 0 0 + 0 + 0 0
Azathioprine 0 0 + 0 + 0 0
Mycophenolate + 0/+ ++ 0 0/+ ++ +
Undesirable effects are listed using the following categories: ++ very common (≥1/10); + common (≥1/100 to <1/10); 0/+ 
uncommon (≥1/1,000 to <1/100); rare( <1/1,000).
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ranged from 12.7% to 23.8%. If patients use the combination of tacrolimus and MMF, the 
reported incidence of diarrhea is even higher. Depending on the dose of tacrolimus, 29.1-44.1 
% of renal transplant patients on 1000 mg MMF and 42.3-63.8% of those on a 2000 mg MMF 
dose suffered from diarrhea (80, 81). The mechanisms responsible for GI intolerance and 
especially diarrhea are still a matter of debate. Some reported that the risk of diarrhea is related 
to the dose and to the peak concentration in the blood (77-79, 82). Others were not able to 
demonstrate a difference in daily MMF dose between patients who suffered from diarrhea 
and those who did not (83). However, the symptoms usually resolve after a dose reduction, a 
temporary interruption, or a complete discontinuation of MMF. The intravenous administration 
of MMF is associated with a higher incidence of GI adverse events, including diarrhea, as 
compared to oral administration and this suggests that systemic MPA and/or its metabolites 
are directly responsible (84-86). 
Acyl glucuronides are reactive electrophilic metabolites of MPA, which can covalently bind to 
the amino acid residues of target proteins in serum and organs like the intestine with induction 
of immunogenic and/ or toxic injury. Villous atrophy in the duodenum (87, 88) and erosive 
inflammation in the ileum (89) have been reported in patients with MMF-associated diarrhea. 
However, no relation was demonstrated between diarrhea and the plasma concentration of 
the reactive acyl glucuronide metabolite of MPA (83, 90). It was suggested that local effects 
of acyl glucuronides metabolites, which are excreted with bile in the intestine, might provoke 
diarrhea (83). Patients who use CsA and carriers of a biliary transporter polymorphism, which 
reduces the excretion of MPA metabolites would therefore be expected to have less diarrhea 
(91). Others suppose that MMF impairs the global enterocyte function through either a higher 
apoptotic rate or an impaired function of the tight junctions leading to leak-flux diarrhea (92).
Besides, some authors have reported severe oral and colonic ulcerations, which were 
suggested to be attributable to MMF toxicity (93-95). In some patients the use of MMF has 
been linked to a Crohn’s-like enterocolitis, which responded to discontinuation of the drug (96). 
The exact mechanism underlying these ulcerations is unknown, but a direct toxic effect of MPA 
on the GI mucosa may be involved.
The enteric coated formulation of MPA, EC-MPS, was developed with the perspective to reduce 
the incidence of GI adverse events that where associated with the use of MMF. In several open-
label studies an improvement in GI tolerability after conversion from MMF to EC-MPS was 
indeed observed (97-99). EC-MPS might therefore be a useful alternative in some patients who 
suffer from MMF-related GI symptoms. However, in two comparative studies with MMF used in 
an equipotent dose, the overall incidence and the profile of GI adverse events were similar in 
patients treated with either MMF or EC-MPS (84, 85).
Immunosuppressive Drugs and the Gastrointestinal Tract in Renal Transplant Patients
37
Azathioprine
In a retrospective review of the literature about side effects of AZA, GI complaints were reported 
in 19 of the 542 patients (100). Approximately 10% of the patients had nausea and/or vomiting, 
and GI symptoms not otherwise specified were reported in 6% of the patients. Anorexia, 
constipation, and gastric or duodenal ulcers are rarely observed. There is only one report on 
chronic diarrhea in a patient with severe villous atrophy and chronic malabsorption possibly 
induced by AZA (101). Although uncommon, acute pancreatitis due to use of AZA is a dreaded 
complication. Acute pancreatitis during AZA treatment is predominantly described in patients 
with inflammatory bowel disease (102). Experimental studies in mice indicate that AZA causes 
biochemical and histological signs of acute pancreatitis and aggravates acinar cell necrosis 
(103, 104). Recently, an association between AZA-induced pancreatitis and certain HLA class II 
genotypes has been described (105).
Several case reports and small patient series identified a syndrome mimicking serious 
gastroenteritis after administration of AZA (106-108). Severe nausea, vomiting and diarrhea 
typically start within a few hours to weeks after introduction of AZA. These symptoms were 
variably accompanied by rash, myalgia, fever, and elevated liver enzymes. This is considered 
to be a form of acute hypersensitivity reaction on AZA. Chronic diarrhea due to AZA is scarcely 
described. 
The occurrence of hepatotoxicity is a real concern for physicians prescribing AZA but is beyond 
the scope of this review.
Corticosteroids
Adverse effects on the GI system caused by CS include peptic ulcers, upper GI bleeding, 
pancreatitis, diverticular perforation, and malakoplakia. A meta-analysis of data from randomized, 
double-blind, controlled trials comparing CS therapy to placebo revealed that GI bleeding or 
perforation occurred in 0.13% of ambulatory CS treated patients who use peptic ulcer prophylaxis 
(109). The risk was increased, but not statistically significant (OR 1.63, 95% confidence interval 
0.42-6.34). Steger et al. demonstrated that there was a trend for a higher risk to develop ulcers in 
renal transplant patients treated with more than 2000 mg methylprednisolone for rejection (110). 
An increased risk of hospitalization (relative risk 2.9; 95% confidence interval 2.1-3.8) because 
of upper GI bleeding among patients prescribed CS has been observed (111). However, 
interpretation is hampered by confounding by the underlying disease.
CS have been listed as a probable cause for acute pancreatitis (112). In contrast, experimental 
studies have shown survival benefit in animal models of acute pancreatitis if they are given 
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hydrocortisone (113). However, no such benefit has been documented in clinical trials on the 
potential of CS to prevent pancreatitis after endoscopic retrograde cholangiopancreatography 
(114).
The use of CS has been also linked to perforation of diverticulas in the sigmoid (115). CS may lead 
to atrophy of lymphoid aggregates and subsequent thinning of the bowel wall. The incidence of 
colonic diverticular perforation in renal transplant patients ranges from 1% to 4% (116, 117).
Finally, colonic malakoplakia, a chronic granulomatous disease, is linked to the use of CS and 
other immunosuppressive drugs (118).
Interaction between drugs targeting the gastrointestinal tract and  
immunosuppressive drugs
Some commonly given GI targeting drugs affect the exposure to immunosuppressive drugs.
The interactions are represented in Table 3 and are described in the following sections.
Prokinetic agents
Prokinetic agents like metoclopramide could increase the bioavailability of CNIs, mTOR 
inhibitors and CS by accelerated gastric emptying while metabolic capacity is less in the distal 
intestine. This phenomenon has been described for the combination of metoclopramide and 
tacrolimus or CsA (119, 120). Moreover, domperidone and ondansetron are substrates for 
ABCB1 and are metabolized by CYP3A4. Interactions with CNIs, mTOR inhibitors and CS might 
thus occur, but they have not been demonstrated. Enhancement of domperidone induced 
parkinsonism in animals by the inhibitory effect of CsA on ABCB1 at the blood-brain barrier is 
the only reported interaction (121).
Antacids
The concomitant use of antacids which contain aluminum and magnesium hydroxides reduces 
the exposure to mycophenolate as a consequence of diminished absorption (122). It is most 
likely explained by chelation, although an increase of the gastric pH with decline of elution and 
hydrolysis of MMF might be an alternative explanation. 
Studies showed that tacrolimus blood levels significantly decreased if tacrolimus solution was 
given together with magnesiumoxide or sodium bicarbonate (123, 124). However, this has 
never been confirmed in patients (125).
Immunosuppressive Drugs and the Gastrointestinal Tract in Renal Transplant Patients
39
Proton pump inhibitors
Combined treatment with MMF and proton pump inhibitors (PPIs) reduces the exposure 
to MPA. (126-130). Studies showed that concomitant use of pantoprazole 40 mg resulted 
in a 34-37% lower exposure to MPA (130, 131). PPIs raise the gastric pH level, which 
results in a decreased de-esterification of MMF and thereby a reduction of the MPA plasma 
concentration (132). However, a higher rate of acute rejection in renal transplant patients 
receiving pantoprazole next to MMF was only established in African Americans (133, 134). The 
pharmacokinetics of EC-MPS is not affected by PPI co-administration as metabolism does not 
depend on the gastric pH (135).
PPIs are metabolized by cytochrome P450 enzymes in humans, most notably by CYP2C19 
but also by CYP3A4. In some reports associations are described between pharmacogenetic 
variability of CYP 2C19 and the extent of interaction with tacrolimus (136, 137). Reduced activity 
of the CYP2C19 enzyme leads to an increased reliance on CYP3A4 for PPI metabolism. In 
this situation, the potential for interaction with tacrolimus, resulting in increased tacrolimus 
levels, is increased. Since the extent of metabolism by CYP2C19 versus CYP3A4 differs for the 
various PPIs, the risk for this type of interaction also varies per PPI (138, 139). Furthermore, the 
frequency of CYP2C19 poor metabolizers is higher in Asians (12% to 27%) than in Caucasians 
(1% to 6%) or African-Americans (2%) (140).
Table 3  
Interactions between commonly used GI targeting drugs and immunosuppressive agents
Prokinetics Antacids Proton 
pump 
inhibitors
H2 
antagonists
H. pylori 
eradication 
Antidiarrheals Laxatives
Tacrolimus ± - ± - + - -
Cyclosporine ± - - - + - -
mTOR 
inhibitors
- - - - +  - -
Corticosteroids - - - - - - -
Azathioprine - - - - - - -
Mycophenolate - + ± - + - ±
Interactions are symbolized by +; possible interactions by ±; absence of interaction by -
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Histamine 2 antagonists
Although histamine 2 (H2) antagonists also suppress gastric acid secretion, their effect on 
gastric pH is less than of PPIs and there is no impact on the exposure to MMF (131). Despite an 
influence of H2 antagonists on ABCB1, there are no known interactions with immunosuppressive 
agents. Of note, it should be serum creatinine usually rises after starting with cimetidine due to 
inhibition of the tubular secretion of creatinine without a change in the glomerular filtration rate.
Helicobacter pylori eradication regimens
Triple therapy based on a PPI combined with claritromycin and amoxicillin and/or metronidazole 
is the established first-line therapy for Helicobacter pylori eradication (141). However, an 
interaction of claritromycin with CNI, mTOR inhibitors or CS can occur via inhibition of CYP3A 
and ABCB1. Therefore, an alternative eradication regimen should be considered in transplant 
patients using these drugs, although intensified therapeutic drug monitoring is also an option. 
A disadvantage of the alternative eradication regimen consisting of PPI, levofloxacin and 
amoxicilline is the rising rates of levofloxacin resistance (141). Moreover, concomitant use of 
metronidazole reduces the exposure to MPA with approximately 19 % in healthy subjects (142). 
This interaction is caused by disruption of the enterohepatic recirculation of MPA (18).
Loperamide and laxatives
Loperamide and most laxatives do not have clinically relevant interactions with the 
immunosuppressive drugs. In rats, it was established that CsA increased the loperamide brain 
concentration by inhibiting ABCB1 in the blood brain barrier (143). However, such an effect has 
never been described for the intestinal ABCB1. The only laxatives showing an interaction with 
immunosuppressive drugs are magnesium containing ones, which reduce the bioavailability of 
MPA.
Conclusion
Most immunosuppressive agents are metabolized to a substantial extent in the GI tract. GI 
orders can therefore affect the exposure to these agents. Knowledge on the involvement of 
transport proteins and metabolizing enzymes will help to better understand the consequences 
of GI tract diseases and disturbances for immunosuppressive therapy in renal transplant 
patients. On the other hand, immunosuppressive agents can have various adverse effects 
on the GI tract, which affect quality of life, and can even have impact on patient or allograft 
survival. For physicians prescribing immunosuppressive drugs to transplant patients it is 
important to realize this reciprocal interaction.
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Abstract
Background: Mycophenolate mofetil (MMF) is the pro drug of mycophenolic acid (MPA). 
Proton pump inhibitors impair the exposure to MPA due to incomplete conversion from MMF. 
Lower exposure to MPA could result in an increased risk of acute rejection. We investigated 
whether MMF-treated renal transplant patients who concomitantly used pantoprazole as ulcer 
prophylaxis, had a higher risk of acute rejection within the first 3 months after transplantation 
than those who used ranitidine.
Methods: We performed a retrospective study in adult patients, who underwent kidney 
transplantation between January 2007 and December 2011. Their immunosuppressive therapy 
consisted of steroids, tacrolimus and MMF and they used either pantoprazole or ranitidine as 
ulcer prophylaxis.
Results: 202 patients were included: 125 using pantoprazole and 77 using ranitidine. There was 
no difference in the number of patients with biopsy-proven acute rejection (BPAR): 13 (10.4%) 
in the pantoprazole group versus 7 (9.1%) in the ranitidine group (NS). Also after correction 
for inequalities between both groups, there was no significant relationship between the risk of 
BPAR and the type of anti-ulcer agent.
Conclusion: There was no evidence for an increased incidence of BPAR in renal transplant 
patients who use pantoprazole in combination with MMF.
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Introduction
Mycophenolate mofetil (MMF) is a commonly used immunosuppressive drug after solid organ 
transplantation and in autoimmune disease. After the intake of MMF, it is rapidly absorbed 
and hydrolyzed to its active metabolite, mycophenolic acid (MPA). MPA reversibly inhibits 
inosine monophosphate dehydrogenase, which is a key enzyme involved in the de novo purine 
synthesis in activated lymphocytes. Adequate exposure to MPA is associated with a decreased 
rate of acute rejection in kidney transplant patients (1-4).
Proton pump inhibitors (PPIs) are frequently prescribed post transplantation as prophylaxis 
for peptic ulcer disease, which is common and can cause significant morbidity and mortality 
(5). During the last years, a series of studies have reported that PPI therapy decreases MPA 
exposure in kidney transplant patients, heart transplant patients, patients with autoimmune 
disease, and healthy volunteers (6-10). Studies showed that concomitant use of pantoprazole 
40 mg resulted in 34-37% lower exposure to MPA (10, 11). PPIs can raise the gastric pH level 
above 4, which results in a decreased de-esterification of MMF (12) and thereby a reduction of 
the MPA plasma concentration.
In our center, peptic ulcer prophylaxis in recipients of a kidney transplant usually consists of 
either the PPI pantoprazole or the histamine 2 (H2) receptor antagonist ranitidine. During the 
first day after administration, H2 receptor antagonists usually elevate the gastric pH to a similar 
degree, or even more, than PPIs (13, 14). However, due to tolerance induction, the effect of 
H2 receptor antagonists on gastric pH rapidly wanes during subsequent days, while the effect 
of PPIs strengthens. Thus, it can be expected that the effect of continuous use of H2 receptor 
antagonists on MPA levels is considerably smaller than of PPIs. Currently, it is unknown 
whether the lower MPA exposure in patients treated with PPI has any clinical implications.
The present study therefore aimed to investigate whether MMF-treated renal transplant patients 
who concomitantly used pantoprazole, had a higher risk of acute rejection within the first three 
months after transplantation than those who used ranitidine.
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Methods
Study design
We performed a retrospective cohort study to investigate whether MMF-treated kidney 
transplant patients, who concomitantly used pantoprazole (n=125), had an increased rate of 
acute rejection within the first three months after renal transplantation, compared with those 
who used ranitidine (n=77). The data were derived from medical records and a local database 
with transplant outcome data. According to Dutch law, Institutional Review Board approval was 
not required.
The primary outcome was the occurrence of biopsy-proven acute rejection (BPAR) within 
the first three months after transplantation. Histological examination and classification were 
done according to the Banff criteria (15). A clinical diagnosis of presumed acute rejection 
was made when serum creatinine levels increased without another explanation and a biopsy 
was not performed. The secondary outcomes were the incidence of BPAR or presumed acute 
rejection within three months after transplantation, acute rejection within six months (BPAR or 
presumed acute rejection), graft survival at six months after transplantation, serum creatinine 
level, estimated glomerular filtration rate (eGFR) calculated by using the MDRD formula and 
proteinuria at three months after transplantation.
Patients
We included all adult patients who underwent renal transplantation in our center between 
January 2007 and December 2011 and used a standard immunosuppressive therapy 
consisting of tacrolimus, prednisone and MMF with either ranitidine or pantoprazole, as 
ulcer prophylaxis. The choice between ranitidine and pantoprazole was made by the treating 
physician and usually depended on pre-existing use of either drug and personal preference of 
the treating physician. Exclusion criteria were: graft loss or death within the first three months 
after transplantation, treatment with drugs known to have a pharmacokinetic interaction with 
MMF (e.g. phosphate binders, rifampicine or colestyramine), intravenous administration of 
MMF, combined use of ranitidine and pantoprazole, and switch between both drugs. Patients 
with a history of bowel surgery were also excluded.
Part of the patients (n=54) received induction therapy, which consisted of basiliximab (n=6), 
daclizumab (n=1), or rituximab (n=47). Rituximab was given within the framework of a blinded, 
prospective, placebo-controlled trial (clinicaltrials.gov; NCT00565331). Patients were treated 
with prednisone 100 mg per day during the first three days after surgery and subsequently with 
prednisone 20-25 mg/day, which was gradually tapered to 0.1 mg/kg/day. On the first day after 
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renal transplantation, tacrolimus was started in a dose of 0.2 mg/kg/day to target the trough 
level between 15 and 20 µg/L. During the first three months after transplantation, the dose 
of tacrolimus was gradually tapered to aim a target range between 5 and 10 µg/L. The initial 
dose of MMF was 1000 mg twice daily and after two weeks this was decreased to 750 mg 
twice daily, except in patients who weighed more than 90 kilograms. If patients suffered from 
leucopoenia or gastrointestinal complaints, the dose of MMF was reduced.
Acute rejections were initially treated with intravenous methylprednisolone 750-1000mg during 
three consecutive days. If this treatment failed, patients received anti-thymocyte globulin (ATG, 
Thymoglobulin®), muromonab (Orthoclone OKT3®), or alemtuzumab (Campath®).
All patients started with either pantoprazole 40 mg/day (some patients started accidentally 
with pantoprazole 20 mg) or ranitidine 150 mg/day. These doses could be increased if patients 
had gastrointestinal complaints. Unless there were still complaints, the ulcer prophylaxis 
was stopped after three months. All patients used co-trimoxazole as pneumocystis jirovecii 
prophylaxis and valganciclovir was prescribed as prophylaxis if the renal transplant recipient 
was seronegative for cytomegalovirus while the donor was seropositive.
Statistical analysis
A threefold increase in the incidence of acute rejection might occur if patients have a 35% 
lower exposure to MPA in consequence of the combined use of pantoprazole and MMF 
in the early period after transplantation (3, 10, 11). We expected a rejection rate of 15% in 
ranitidine-treated patients and made a conservative estimate of the rejection rate of 30% in the 
pantoprazole-treated patients. Based on these rejection rates, a power of 0.8 and a type I error 
probability of 0.05, a sample size of 120 patients was required.
Normally distributed data are presented as mean with standard deviation (SD). Before 
analysis, data with a skewed distribution like cold ischemia time, PRA and proteinuria were 
logarithmically transformed. We analysed our data with X2-test and unpaired T-test where 
appropriate. A multiple logistic regression analysis was carried out to evaluate whether 
variables, which were not equally distributed over both groups, affected the risk of BPAR. All 
statistical analyses were performed by using SPSS software version 20.0 (SPSS Inc., Chicago, 
IL, USA).
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Table 1   
Patient characteristics
Pantoprazole 
(n=125)
Ranitidine  
(n=77)
Significance 
p-value
Male (%) 61.6 66.2 NS
Age (years) 47.7 (12.8) 46.7 (13.3) NS
Caucasian (%) 98.4 98.7 NS
Weight (kg) 74.3 (13.5) 75.4 (15.2) NS
Length (cm) 173.9 (9.7) 175.1 (10.5) NS
Living donor (%) 66.4 77.9 NS
PRA (%) 7.4 (1.2) 7.1 (1.3) NS
Retransplantation (%) 15.2 7.8 NS
Cold ischemia time in deceased donors (h) 18.05 (5.43) 15.17 (5.16) NS
HLA mismatches on A, B and DR 3.2 (1.5) 3.2 (1.6) NS
Donor age (years) 51.5 (10.8) 51.7 (11.3) NS
CMV status (%)
 D+/R+
 D-/R+
 D+/R-
 D-/R-
23.2
18.4
27.2
30.4
26.0
23.4
22.1
27.3
NS
NS
NS
NS
Induction therapy (%)
Rituximab
Basiliximab
Daclizumab
17.6
3.2
0.8
32.5
2.6
0.0
<0.05
NS
NS
Delayed graft function (%) 2.4 3.9 NS
Cumulative dose of MMF in 3 months (g) 142.8 (18.0) 144.3 (18.1) NS
Daily dose of prednisone at 3 months (mg) 10.1 (4.0) 10.8 (3.8) NS
Daily dose of tacrolimus at 3 months (mg) 7.5 (4.2) 7.3 (4.0) NS
Data are shown as mean (standard deviation) or percentage. Abbreviations: PRA: panel reactive antigens; HLA: human 
leucocyte antigen; CMV: cytomegalovirus; D: donor; R: recipient; + seropositive, - seronegative, MMF: mycophenolate 
mofetil. NS: not significant.
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Results
The characteristics of the 202 patients who met the inclusion and exclusion criteria are 
summarized in Table 1. The number of patients who received rituximab induction therapy 
differed significantly between both groups. Small inequalities were present regarding cold 
ischemia time, retransplantations, donor type, and cumulative dose of MMF. The daily dose of 
pantoprazole varied between 20 mg and 80 mg and the mean cumulative dose in three months 
was 3.9 g (standard deviation 1.0). The ranitidine dose varied between 150 mg and 300 mg per 
day, with a mean cumulative dose in three months of 14.4 g (2.4). 
The percentage of patients with BPAR within three months after transplantation did not differ 
significantly between both groups: 10.4% (n=13) in patients who used pantoprazole and 9.1 
% (n=7) in patients who used ranitidine. Thus, the difference in percentage of BPAR between 
both groups is 1.3% (95% confidence interval -6.9% - 9.5%). There was also not a significant 
difference in the percentage of patients who had either BPAR or presumed acute rejection 
within three months after transplantation (20.0% (n=25) versus 19.5% (n=15)). In addition, 
the percentage of patients with BPAR or presumed acute rejection within six months after 
transplantation did not differ significantly between both groups (Table 2). The cumulative dose 
of MMF in patients with BPAR was 133.1 gram (14.3) and in patients without BPAR, it was 
144.5 gram (18.1) (p<0.01). Creatinine level, eGFR, and level of proteinuria at three months 
after transplantation did not differ significantly between both groups (Table 3). Graft and patient 
survival was 100% in both groups at six months after transplantation.
Multiple logistic regression analysis was performed with the following covariates: race, age 
of the recipient, rituximab induction therapy, retransplantation, donor type, cold ischemia 
time, panel reactive antibodies (PRA), human leukocyte antigen (HLA) mismatches, delayed 
graft function, cumulative dose of MMF, and type of anti-ulcer agent. Using BPAR within three 
months as dependent variable, the only statistically significant covariates were cumulative dose 
of MMF (p<0.01), race (p<0.05) and retransplantation (p<0.05). There was no effect of the 
type of anti-ulcer agent on the risk of BPAR.
Since the dose of pantoprazole varied between patients, we evaluated the correlation between 
cumulative dose of pantoprazole within the first three months after transplantation and the 
incidence of BPAR. There was no significant association between exposure to pantoprazole 
and risk of acute rejection.
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Table 2
Percentage of patients with acute rejections within 3 or 6 months after transplantation
Pantoprazole 
(n=125)
Ranitidine 
(n=77)
Significance 
p-value 
BPAR within 3 months 10.4% 9.1% NS
BPAR or presumed acute rejection within 3 months 20.0% 19.5% NS
BPAR within 6 months 12.0% 10.4% NS
BPAR or presumed acute rejection within 6 months 21.6% 20.8% NS
Abbreviations: BPAR: biopsy-proven acute rejection. NS: not significant.
Table 3 
Creatinine, eGFR and proteinuria at 3 months after transplantation in both groups
Pantoprazole 
(n=125)
Ranitidine 
(n=77)
Significance 
p-value
Creatinine (mg/dL) 1.5 (0.4) 1.5 (0.4) NS
eGFR (ml/min/1.73m2) 49.5 (12.3) 50.7 (12.5) NS
Proteinuria (g/10mmol creatinine) 0.25 (2.68) 0.15 (0.25) NS
Abbreviations: eGFR: estimated glomerular filtration rate. NS: not significant
Discussion
In this retrospective study we did not observe an increased risk of acute rejection within the 
first three months after renal transplantation in patients using pantoprazole in combination with 
MMF. Accordingly, there was no relationship between the dose of pantoprazole and the risk of 
acute rejection.
After oral administration, MMF is rapidly absorbed and undergoes extensive presystemic de-
esterification by esterases to MPA. The MPA peak concentration is reached within 1-2 hours. 
Several investigators showed that PPI co-medication leads to a 34-37% reduction of the MPA 
exposure (10, 11). The impairment of MPA exposure following co-administration of MMF and 
PPI has been demonstrated for pantoprazole, lansoprazole, and omeprazole (6-11). In our 
center, we are used to prescribe pantoprazole as PPI for peptic ulcer prophylaxis. Pantoprazole 
40 mg produces a strong and consistent gastric acid suppression (16). Morning or evening 
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intake of pantoprazole is irrelevant because intra-gastric pH elevation under PPI treatment is 
a permanent effect due to the irreversible inhibition of the gastric proton pump (16). A higher 
dose of pantoprazole leads to a higher gastric pH and to a lower solubility of MMF since it 
was approximately 4 mg/L in a buffer with a pH of 4, but only 0.24 mg/L at a pH of 5.2 and 
only 0.04 mg/L at a pH of 7 (17). A secondary peak in the concentration-time profile of MPA 
occurs after 6 to 12 hours because of enterohepatic circulation. This secondary peak in the 
concentration-time curve is not reduced by use of PPI since no significant changes in MPA 
plasma concentrations between 2 and 12 hours after the intake were found in patients using a 
PPI (10).
Previous studies have shown that a lower exposure to MPA increases the incidence of acute 
rejection after renal transplantation (1-4). On the basis of these data, we hypothesized that the 
use of PPI in MMF treated renal transplant patients might result in an increased incidence of 
acute rejection. As far as we know our study is the first that specifically addresses this issue.
The risk of acute rejection did not differ between pantoprazole and ranitidine treated patients, 
despite a slightly lower total cumulative dose of MMF in the pantoprazole group. Based 
on an approximately 35% lower exposure to MPA in patients who used the combination of 
pantoprazole and MMF in the early time after transplantation, a threefold increase in the 
incidence of acute rejection might occur (3, 10, 11). The rejection incidence of 10.4% in the 
pantoprazole group as well as the relatively narrow 95% confidence interval for the difference 
with the ranitidine group (-6.9% – 9.5%) make such an increase in rejection incidence highly 
unlikely.
While most studies indicate that the combined use of PPI and MMF leads to a lower MPA 
exposure, Kiberd et al. recently found no significant impact of PPI use on total MPA exposure 
at day 5 after transplantation, although blood levels at 2 and 12 hours post-dose were 
significantly reduced (18). Because we did not measure MPA levels and gastric pH, we 
were not able to show a pharmacokinetic interaction between MMF and PPI in our patients. 
However, the magnitude of such an effect was apparently not large enough to have clinical 
consequences. 
Moreover, our study is limited by its retrospective design, which impedes correction for 
unknown confounders. Furthermore, it should be noted that patients who used cyclosporine 
were not included in this study. Because cyclosporine has an inhibitory effect on the 
enterohepatic circulation of MPA, cyclosporine-treated patients might be more prone to 
underexposure to MPA if MMF is combined with a PPI. Similarly, potential underexposure 
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to MPA might be more problematic in African American patients who were nearly absent in 
our study population (19). Finally, since we only investigated the effect of concomitant use 
of pantoprazole and MMF during the first three months after transplantation, we cannot rule 
out that longstanding concomitant use does increase the incidence of rejection. However, 
David-Neto et al. recently showed that the effect of simultaneous use of PPI and MMF on 
MPA exposure was particularly present in the first week post-transplantation (20). Moreover, 
an increased rejection incidence has especially been associated with inadequate exposure to 
MPA in the early period after transplantation (2, 4).
In conclusion, we found no evidence for a higher incidence of acute rejection in patients using 
pantoprazole in combination with MMF. This was supported by the absence of a significant 
relationship between the dose of pantoprazole and incidence of acute rejection.
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Abstract
Background: Diarrhea is a frequent adverse event in patients treated with the combination of 
tacrolimus and mycophenolate mofetil (MMF). In case of severe diarrhea, the total exposure 
to tacrolimus can substantially increase, which is reflected in a rise of the pre-dose trough 
level (C0). In mild diarrhea (2-3 stools per day), an increased exposure might occur without 
trough levels exceeding the target range, resulting in “silent” chronic tacrolimus overexposure. 
The aim was to assess the degree of unnoticed tacrolimus overexposure in renal transplant 
patients with mild diarrhea while on treatment with tacrolimus and MMF.
Methods: A prospective pharmacokinetic study was performed in 12 recipients of a renal 
allograft using a combination of tacrolimus and MMF with mild diarrhea and in 12 controls. 
Tacrolimus levels were assessed by a validated dried blood spot method for sampling and 
measurement. 
Results: The C0 did not differ between patients with mild diarrhea and controls (9.6 µg/L (95% 
confidence interval 8.6-10.9) and 8.3 µg/L (6.9-9.9)). In addition there was no significant 
difference in the 12 hours area under the curve (AUC(0-12)) between patients with mild diarrhea 
and controls (185.6 µg.h/L (153.6-224.2) versus 170.5 µg.h/L (137.2-221.8)). As a result, the 
ratio between AUC(0-12) and C0 was similar in both groups (19.2 (17.5-21.1) versus, 20.6 (19.0-
22.4)). The intra-individual variability in tacrolimus exposure was limited and not affected by the 
presence of mild diarrhea.
Conclusion: We found no evidence for the presence of hidden tacrolimus overexposure in 
patients with mild diarrhea while on treatment with tacrolimus and MMF. 
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Introduction 
Tacrolimus and mycophenolate mofetil (MMF) belong to the standard immunosuppressive 
drugs after renal transplantation. Tacrolimus has a narrow therapeutic window with 
overexposure leading to acute and chronic forms of nephrotoxicity. Therapeutic drug 
monitoring (TDM) is therefore commonly applied in patients who are treated with tacrolimus. 
The area under the concentration versus time curve (AUC) as a measure of the total exposure 
is thought to be the intermediary link between the dose of tacrolimus administered and 
the eventual response (1). In most transplantation centers, however, TDM is performed by 
measuring the trough level of the drug, and by adjusting the dose to reach or maintain a target 
trough level range. Notably, the relationship between the AUC on the one hand and trough 
levels on the other hand, is imperfect and an increase in the AUC of tacrolimus may not always 
be translated into a clear rise in trough level (2, 3).
Diarrhea is a frequent adverse event in patients treated with the combination of tacrolimus 
and MMF and has an important impact on the pharmacokinetics of tacrolimus (4). The 
incidence of diarrhea, mostly noninfectious in nature, in patients using tacrolimus and MMF 
has been reported to range from 29% to 64%, depending on the dosages that were used 
and the duration of observation (5). In patients experiencing severe diarrhea (more than 3 
loose stools daily), the exposure to tacrolimus (AUC) can increase substantially which is also 
reflected in an elevation of the trough level (6). Diarrhea precedes the rise in tacrolimus blood 
levels, indicating that the diarrhea is the cause of the increase of tacrolimus exposure and 
not a consequence (6). Various explanations for the effect of severe diarrhea on the exposure 
to tacrolimus have been proposed but the most important one is enhanced absorption as a 
consequence of a damaged intestinal barrier and reduced intestinal metabolism (4, 7).
Mild diarrhea (2-3 stools per day) is more common and not always reported to the treating 
physician (8). Like in more severe cases, mild diarrhea might affect the exposure to tacrolimus, 
but probably to a lesser extent. Since it is known that an increased exposure (AUC) is not 
necessarily reflected by a trough level exceeding the target range (2), ongoing mild diarrhea 
might result in unnoticed chronic tacrolimus overexposure leading to irreversible nephrotoxicity. 
Moreover, variation in the frequency and consistency of stools might be associated with a 
higher within-patient variability in tacrolimus exposure, which has been reported to be a risk 
factor for poor long-term outcome after renal transplantation (9).
The current study aimed to investigate whether renal transplant patients with mild diarrhea 
during treatment with tacrolimus and MMF suffer from overexposure to tacrolimus as measured 
by the AUC of the drug, which may not be detected by standard TDM based on measurement 
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of trough levels only. Timely adjustment of the dose of tacrolimus in these patients might 
prevent chronic nephrotoxicity and result in improved long-term outcome of the renal graft.
Patients and methods
Patients
We selected twelve patients with persistent mild diarrhea, defined as an average stool 
frequency of 2-3 times daily or loose stools once daily during the last two weeks prior to 
inclusion. Twelve other patients with an average stool frequency of 1 time per day or less and a 
normal consistency of stools during the last two weeks prior to inclusion, served as controls. All 
participants were adults who received a renal allograft from either a living or a cadaveric donor 
at least two months before inclusion. They were treated with a standard immunosuppressive 
regimen consisting of oral tacrolimus (Prograft®) b.i.d., mycophenolate mofetil (CellCept®) 
750 mg b.i.d., and corticosteroids 0.10-0.15 mg/kg per day depending on the time after 
transplantation. The dosing of tacrolimus was based on TDM. To be included in the study, 
the trough level of tacrolimus had to be within the target range (5-10 µg/L) at two subsequent 
occasions.
Exclusion criteria were a history of bowel resection, severe diarrhea (more than 3 loose stools 
daily), fever, rectal blood loss, signs of an active cytomegalovirus infection, and a change in 
tacrolimus dose within one week prior to inclusion.
All patients gave written informed consent. The study was approved by the local ethics 
committee and conducted in accordance with the Helsinki Declaration.
Methods
Instead of measuring trough levels only, a full pharmacokinetic profile of tacrolimus was 
recorded to be able to calculate AUC(0-12) to the drug. The pharmacokinetic profile of tacrolimus 
was obtained at two occasions within a time span of five days, with a minimum interval of one 
day between the two assessments. At each occasion, the first measurement of the whole 
blood tacrolimus concentration (C0) took place 14 hours after the intake of the last evening 
dose, after an overnight fasting. Subsequently, the morning dose of tacrolimus was taken and 
blood samples were collected at 1, 2, 4, 6, 9 and 12 hours after ingestion. The participants 
remained fasted until two hours after the intake of tacrolimus, since it has been reported that 
the tacrolimus concentration profile can be influenced by meal consumption (10). A validated 
dried blood spot method for sampling and detection of tacrolimus was used, which allowed 
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that participants took their own blood samples at home (11). Using this technique, capillary 
blood is obtained by a finger prick with an automatic lancet by the patients themselves. Then, 
the drop of blood is applied to the sampling paper. After drying and transport of the paper 
to the laboratory, a disk from the blood spot is punched out and further analyzed by high-
performance liquid chromatography-tandem mass spectrometry (8). Participants received 
thorough training in using this method prior to performing the pharmacokinetic measurements. 
Pharmacokinetic parameters were assessed with noncompartmental methods. C0 and Clast 
were read directly from the pharmacokinetic curves. The AUC(0-12) was calculated by the linear-
log trapezoidal rule. For each patient, the average value of the parameters measured on both 
occasions was used for further analysis
Furthermore, participants completed two questionnaires, the GIQLI (gastrointestinal quality of 
life index) (12) and GSRS (gastrointestinal symptoms rating scale) (13), during their training 
visit. In the GIQLI, the absence of symptoms results in a higher score, while in the GSRS the 
score becomes higher in the presence of symptoms.
Statistical analysis
Skewed pharmacokinetic data, except Tmax, were described with the geometric mean and a 
95% confidence interval. Tmax was shown as median and range. To assess whether pre-dose 
trough concentrations in patients with and without mild diarrhea reflected the total exposure in 
a similar way, we calculated the ratio between AUC(0-12)  and C0. Differences between groups 
were analysed with the independent samples T-test, non-parametric Wilcoxon rank-sum test, 
and chi-square test dependent on distributional characteristics. The correlation between pre-
dose trough concentrations and AUC(0-12) values were assessed with the Pearson correlation 
coefficient using log-transformed parameters. A multivariate analysis was performed to 
evaluate the effect of possible other determinants than diarrhea on the AUC(0-12). To assess the 
intra-individual variability in pharmacokinetic parameters, we used the formula as described by 
Borra et al. (9).
The primary outcome parameter in this study was the ratio between AUC(0-12) and C0.  
A difference of 30% in this ratio was considered to be clinically relevant. The sample size 
calculation was based on this difference, an estimated standard deviation of 20 µg.h/L in 
AUC(0-12) (2), a power of 0.8 and a type I error probability of 0.05. All statistical analyses were 
performed by using SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA).
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Results
The characteristics of the twelve patients with mild diarrhea and twelve controls are 
summarized in Table 1. All participants were of Caucasian ancestry. Although none of the 
participants had diabetic nephropathy as original kidney disease, six of the patients with mild 
diarrhea (50%) and two of the control patients (16%) suffered from diabetes mellitus at the time 
of investigation; new-onset diabetes after transplantation (NODAT) in four and one of these 
cases, respectively. The weight-adjusted MMF dose did not differ between the groups.
Table 1
Characteristics of the patients
Patients with mild diarrhea
n=12
Controls 
n=12
Male/female (n) 7/5 4/8
Age (years)* 56 (10.2) 50 (13.2)
Weight  (kg)* 85.2 (13.8) 74.9 (14.3)
Donor type: living/deceased (n) 10/2 4/8
Hepatitis C (%) 0 0 
Pre-existent diabetes mellitus (%) 16 8 
NODAT (%)** 33 8 
Hematocrit (%)* 0.38 (0.03) 0.39 (0.05)
Serum creatinine (µmol/L)* 118 (28) 117 (15)
Serum albumin (mg/L)* 38.8 (3.0) 40.8 (2.1)
Time post-transplant (months)* 4.7 (1.4) 4.3 (1.4)
Tacrolimus dose (mg/kg/day)* 0.07 (0.04) 0.10 (0.05)
Steroid dose (mg/kg/day)* 0.11 (0.02) 0.12 (0.04)
Mycophenolate mofetil dose (mg/kg/day) 19.2 (3.0) 20.3 (4.8)
*Shown as mean (standard deviation); ** new-onset diabetes after transplantation.
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The mean daily dose of tacrolimus was 6.0 mg (standard deviation 3.3) in patients with mild 
diarrhea and 7.1 mg (3.6) in the controls (NS). There were no significant differences in the  
pre- and post-dose trough levels (C0 and Clast) and the total exposure to tacrolimus  
(AUC(0-12)) (Table 2). Likewise, the maximum concentration of tacrolimus (C
max), the time to 
achieve maximal concentration (Tmax), and the elimination half life (T½) were not significantly 
different. The ratio between AUC(0-12) and C0 of tacrolimus, which was the primary endpoint of 
the study, did not differ between the patients with mild diarrhea and the controls. Moreover, 
there was a similarly high correlation between the C0 and AUC(0-12) in each group with no 
difference in the regression coefficient (Figure 1).
Table 2
Pharmacokinetic parameters of tacrolimus
Patients with mild diarrhea Controls P
C0 (µg/L) 9.6 (8.6-10.9) 8.3 (6.9-9.9) NS
Cmax (µg/L) 28.7 (20.9-39.6) 29.7 (21.7-40.5) NS
Tmax (h) 1.0 (0.92-8.9) 1.5 (0.92-2.07) NS
Clast (µg/L) 10.4 (8.8-12.2) 8.5 (8.6-13.5) NS
T½ (h) 10.4 (8.8-12.2) 10.8 (8.6-13.5) NS
AUC(0-12) (µg.h/L) 185.6 (153.6-224.2) 170.5 (137.2-211.8) NS
AUC(0-12):C0 19.2 (17.5-21.1) 20.6 (19.0-22.4) NS
Data are shown as geometric mean (95% confidence interval) except in the case of Tmax. which is shown as median and 
range. C0: pre-dose trough level; Cmax: maximal concentration; Tmax: time for reaching Cmax; Clast: post-dose trough 
level; T½: elimination half time; AUC(0-12): area under the curve in an 12 hours period.
Because of inequalities in group composition concerning diabetes, gender, age, donor type, 
weight, and tacrolimus dose, linear regression analysis was performed with these items as 
covariables. However, also in this multivariate analysis, there was no effect of mild diarrhea on 
the ratio between AUC(0-12) and C0.
As expected, the scores on the questionnaire GSRS were higher in patients with diarrhea 
than in the controls, and this was especially the case for items related to diarrhea (Table 3). 
For the GIQLI, the difference in the scores on diarrhea related items was not translated into a 
significant difference between groups in the overall score. Within the total study population, 
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there was no significant correlation between the scores on diarrhea related items of the GSRS 
or GIQLI on the one hand and the ratio between AUC(0-12) and C0 of tacrolimus on the other 
hand.
Figure 1 
Correlation between tacrolimus trough level (C0) and 12 hours area under the curve (AUC0-12). 
Open squares and dotted line denote patients with mild diarrhea; closed circles and solid line denote controls. The 
correlation coefficient was 0.91 in the patients with mild diarrhea, and 0.90 in the controls.
The mean within-patient variability for AUC(0-12) of tacrolimus was 6.0% (2.3-9.6%) in patients 
with diarrhea and 5.4% (2.4-8.4) in the controls (NS). For the C0 these values were 6.2% (3.3-
12.9) and 4.0% (1.8-5.7), respectively (NS). For the subgroups of patients with and without 
diarrhea and for the total study population, there was a good agreement between the AUC(0-12) 
of tacrolimus measured on both occasions, with a Pearson correlation coefficient of 0.91 and 
0.90, respectively (Figure 2).
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Table 3
Scores on the questionnaires GSRS and GIQLI
Patients with mild diarrhea
(n=12)
Controls
(n=12)
P
GSRS score
     Diarrhea related items
29.3 (7.9)
4.3 (2.0)
22.2 (4.4)
2.3 (0.5)
<0.05
<0.01
GIQLI score
     Diarrhea related items
111.0 (12.9)
7.3 (2.8)
115.9 (9.6)
9.8 (1.4)
NS
<0.05
Scores are shown as mean (standard deviation).
Discussion
The main finding of this study is that mild diarrhea was not associated with hidden overexposure 
to tacrolimus in renal transplant patients treated with the combination of MMF and tacrolimus 
in whom TDM for tacrolimus trough levels was applied. Moreover, a strong correlation between 
trough level and AUC(0-12) was present and the within-patient variability of tacrolimus exposure 
was not increased in patients with mild diarrhea as compared to patients with normal stools.
After oral ingestion, tacrolimus is preferentially absorbed in the duodenum and jejunum with 
highly variable pharmacokinetics. It is metabolized by cytochrome P450 3A4 and 3A5 isoforms 
in the liver and the intestinal mucosa. In addition, tacrolimus is a substrate for drug efflux pump 
ABCB1, which actively transports the drug from the mucosal cells back into the intestinal lumen 
(14). Polymorphisms of genes encoding for these cytochrome isoforms and ABCB1 contribute 
to a high inter-individual variability in the pharmacokinetics of tacrolimus (1). Furthermore, the 
blood levels of tacrolimus are affected by exogenous factors like diarrhea and co-medication.
The increase in tacrolimus exposure during severe diarrhea could have several causes. Firstly, 
the bioavailability of tacrolimus can be raised by reduced enzymatic activity of the CYP3A 
system and/or ABCB1in enterocytes that are damaged by intestinal inflammation and infection 
(4, 7, 14). Secondly, due to a shortened ileal transit time during diarrhea, a higher amount 
of tacrolimus may be delivered to the colon, where lower metabolic activity of CYP3A could 
result in increased absorption (15). Observations supporting this theory were made in a renal 
transplant patient with a short bowel syndrome where target tacrolimus levels were achieved 
with a very low dose, and in pigs that showed an increase in tacrolimus levels after resection 
of the small intestine (16, 17). Additional explanations for an increased exposure to tacrolimus 
during diarrhea are hemoconcentration, reduced hepatic metabolism, and fasting (7).
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Figure 2 
Repeatability of measurement of AUC(0-12) of tacrolimus in all participants.
A Correlation between first and second measurement. Correlation coefficient 0.89 (P<0.001).  
B Bland-Altman plot of difference between measurements versus the mean value. 
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How the combined use of tacrolimus and MMF so frequently causes diarrhea is not completely 
elucidated. Data from dose-finding trials for MMF and from a study in which patients were 
randomized to a low, intermediate or high target AUC of mycophenolic acid showed that 
diarrhea was correlated with the dose of MMF (18, 19). On the other hand, a difference in dose 
of MMF comparing patients with diarrhea and controls could not be established (20), although 
symptoms mostly resolved after dose decrement. Several authors reported a loss of the normal 
villous structure of the small bowel during the use of MMF (21-23). Therefore, one might expect 
an effect of MMF induced diarrhea on the intestinal metabolism and absorption of tacrolimus. 
Indeed, Fruhwirth et al. have described a case of elevated tacrolimus trough levels during MMF 
induced diarrhea (24). The trough level of tacrolimus nearly doubled after starting MMF which 
was complicated by diarrheal stools with a frequency of three to four times per day.
Although in our patients the presence of intestinal complaints was confirmed by the results 
of the GSRS and GIQLI questionnaires, the mild diarrhea did not lead to hidden tacrolimus 
exposure. Accordingly, the ratio between AUC(0-12) and C0 did not differ between the two 
groups, as was reflected in nearly identical regression lines with a high correlation coefficient. 
Measuring the trough level appears therefore sufficient to avoid substantial overexposure to 
tacrolimus, also in patients with mild diarrhea. The correlation between pre-dose trough level 
and AUC(0-12) was even stronger than reported in many other studies, which may be the result 
of measuring at more than 2 months post transplantation (2, 3).
Remarkably few data have been published on the intra-individual variability in tacrolimus 
exposure (2, 9). The repeated measurements in our study allowed to address this issue, 
although the sample size was limited and we only measured twice. A Bland-Altman plot 
showed that the majority of differences in measured AUC was within two standard deviations of 
the mean difference, indicating a low intra-individual variability. 
As mentioned before, polymorphisms of genes encoding for the cytochrome 3A isoforms and 
ABCB1 in different populations affect the exposure to tacrolimus. However, all participants in 
our study were of Caucasian ancestry.
For this study on the pharmacokinetics of tacrolimus we used the innovative ‘dried blood spot’ 
technique. This technique requires careful training of the patients involved, but then obviates 
the need for hospital visits, phlebotomies, and clinical research facilities. Therefore this 
technique seems suitable not only for routine TDM but also for observational pharmacokinetic 
studies in a day-to-day clinical setting.
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In conclusion, we could not demonstrate hidden overexposure to tacrolimus in renal transplant 
patients with mild diarrhea. The intra-individual variability in tacrolimus exposure was limited, 
and was not increased by mild diarrhea. Measuring tacrolimus trough levels appears to suffice 
for the prevention of substantial overexposure in these patients.  
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Abstract
Background: Development of a clinically applicable limited sampling strategy for ambulatory 
Caucasian kidney transplant patients to estimate AUC0-24 of prolonged-release tacrolimus.
Methods: 26 kidney recipients, at least 6 months after transplantation, receiving prolonged-
release tacrolimus were enrolled. In each patient, seven blood samples were collected during 
a period of 24 hours by use of the validated dried blood spot method. Best subset selection 
multiple linear regression was performed to derive LSS. The equations were constrained to 
include a maximum of three samples collected within 4 hours after the intake to maintain 
clinical applicability. To assess the predictive performance of LSS, residuals for each patient 
were calculated based on models fitted to a dataset where that patient was omitted. 
Results: The prediction formula for the AUC0-24 using the time points 0, 2, and 4 hours after 
ingestion (C0h-C2h-C4h) provided the highest correlation with the AUC0-24 (r
2 = 0.95): AUC0-24  = 
44.9 + 8.9xC0h + 2.1xC2h + 7.6 xC4h. Measures for bias and precision, i.e. median percentage 
prediction error (MPPE) and median absolute prediction error (MAPE), were 0.4% and 4.8%, 
respectively. For the same patients, the correlation between C24h and AUC0-24 was worse (r
2 = 
0.77) while MPPE and MAPE were 6.2% and 7.2%, respectively.
Conclusion: In the outpatient department, a LSS using C0h-C2h-C4h can be used for reliable 
estimation of the AUC0-24 of prolonged-release tacrolimus..
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Introduction
Tacrolimus is a usual component of the immunosuppressive regimen after renal 
transplantation. While it was developed as an oral twice-daily formulation, a prolonged-
release once-daily formulation was launched a few years ago. The efficacy and safety profile 
of prolonged-release tacrolimus are comparable to that of the twice-daily formulation (1, 
2). Kuijpers et al. demonstrated that the once-daily administration of tacrolimus improves 
adherence, which might ultimately contribute to better graft outcomes (3). Moreover, intra-
patient variability in exposure is somewhat lower with the prolonged-release formulation (4).
Although the relationship between tacrolimus exposure and clinical response has not 
yet been fully established, therapeutic drug monitoring (TDM), i.e. individualization of the 
dose based on concentration measurements, is indicated for tacrolimus. TDM aims to 
improve the efficacy of tacrolimus, prevents overexposure and associated adverse effects, 
and detects drug interactions or unexpected pharmacogenetic influences on exposure 
to this immunosuppressive drug (5). In an expert meeting it was concluded that the area 
under the concentration versus time curve (AUC), which is calculated on the basis of a 
full pharmacokinetic profile, is the best measure of exposure to tacrolimus (5). However, 
assessment of a full pharmacokinetic profile requires the collection of many blood samples 
and is therefore costly, time consuming and uncomfortable, in particular for ambulatory 
patients. These drawbacks hinder recording of the AUC in routine practice. Trough levels are 
commonly used to estimate exposure since they show a moderate to high correlation with AUC 
(2, 6-9). In spite of this moderate to high correlation, AUC can vary up to twofold for the same 
trough level. For that reason concerns have been raised about the use of the trough level (10).
A more reliable estimation of the total exposure can be obtained by a limited sampling strategy 
(LSS). This means sampling at limited or optimal sampling times, still allowing for an accurate 
and precise estimation of the AUC (11, 12). Clearly, a LSS also overcomes logistical and 
financial disadvantages of a full pharmacokinetic profile. However, an appropriate LSS for 
ambulatory Caucasian renal transplant patients who use prolonged-release tacrolimus is not 
available. Therefore the aim of this study was to develop a clinically applicable LSS to estimate 
the AUC0-24 of prolonged-release tacrolimus in them. This would also allow us to assess the 
performance of the trough level, as a single sample, to predict the AUC0-24 of prolonged-release 
tacrolimus.  
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Patients and methods
Study design and population
We carried out a prospective pharmacokinetic study to assess tacrolimus concentrations 
during a period of 24 hours after ingestion of prolonged-release tacrolimus in the morning.
Adult renal transplant patients with a stable graft function were eligible for enrolment if they 
used prolonged-release tacrolimus (Advagraf®, Astellas Pharma) of which the dose was not 
altered during the last visit to the outpatient clinic, and the two most recently measured trough 
levels were within the target range of 5-10 µg/L. Patients were excluded if they were unable 
to perform the home-based dried blood spot measurements of tacrolimus levels (see below) 
or if they had diarrhea (more than 3 stools per day) during the preceding 14 days, as we 
considered that diarrhea might affect the ratio between AUC0-24 and trough levels (13).
The study was approved by the local ethics committee and conducted in accordance with the 
1964 Helsinki Declaration and its later amendments. Informed consent was obtained from all 
individual participants included in the study.
Measurements
A validated dried blood spot method for sampling and analysis of tacrolimus was used, 
which allowed participants to take their own blood samples at home (14). Accuracy and intra- 
and interassay precision were <15% and <7.5%, respectively. Using this method, capillary 
blood is obtained by a finger prick with an automatic lancet by the patients themselves. 
Subsequently, the first two drops of blood are applied to the sampling paper to fill two 
8-mm premarked circles for duplicate sampling. After at least 10 minutes drying at room 
temperature, the samples are stored in a sealed plastic bag and sent by regular post to the 
laboratory. Here, the disks from the blood spot are punched out, extracted and analyzed by 
a specific high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/
MS) method. Participants received thorough training in using this method prior to performing 
the pharmacokinetic measurements and they could only be included if their test blood sample 
passed the quality control. 
Each pharmacokinetic profile started with measurement of the whole blood tacrolimus 
concentration at 24 hours after the previous morning ingestion of prolonged-release tacrolimus 
and after overnight fasting (C0). Subsequently, prolonged-release tacrolimus was taken and 
blood samples were collected at 1, 2, 4, 8, 12 and 24 hours after the ingestion. On the day of 
the measurements, all participants took prolonged-release tacrolimus on an empty stomach 
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and refrained from food intake until two hours after its ingestion since it has been reported 
that the tacrolimus concentration profile can be influenced by meal consumption (15). 
Administration of prolonged-release tacrolimus on an empty stomach is also recommended in 
the product information.
Pharmacokinetic parameters were assessed with noncompartmental methods using 
WinNonLin version 5.0 (Pharsight Co version 5.0, Mountain View, California). The AUC0-24 
was calculated by the linear-log trapezoidal rule. C0, C24, the maximum blood concentration 
(Cmax) and time required to reach it (Tmax) were directly read from the pharmacokinetic curves. 
Elimination rate constant β was obtained by least squares linear regression analysis on 
logarithmic concentrations versus time post-dose, with the slope of the regression line being 
-β/2.303. Apparent clearance (Cl/F where F is bioavailability) was calculated by dividing dose 
by AUC0-24 and apparent volume of distribution (Vd/F) was obtained by dividing Cl/F by β. 
Statistical analysis
Loose concentrations and pharmacokinetic parameters were described with a geometric mean 
and 95% confidence interval. Tmax and daily tacrolimus dose were presented as median and 
range. The other data were shown as median with interquartile range. Correlations between 
numerical variables were calculated using the non-parametric Spearman’s rank correlation 
coefficient (rho). 
We carried out best subset selection multiple linear regression to derive limited sampling 
equations which predicted the AUC0-24. Models were constrained to include a maximum of three 
samples collected within 4 hours after the intake to maintain clinical applicability for patients in 
the outpatient department. We also developed models with a maximum of three samples within 
12 hours after the intake since some patients execute home-based measurements by use of 
the dried blood spot technique. As they don’t need to stay in the outpatient department for the 
measurements, the time span of the LSS is less relevant. We calculated the average adjusted 
r square for all subsets containing one, two, or three samples and the model with the highest 
average r square was chosen. 
To assess the predictive performances of the models we calculated residuals for each patient 
based on models fitted to a dataset where that patient was omitted (jackknife analysis) (12). 
Potential bias in the predictions was assessed by using median percentage prediction error 
(MPPE). For this measure, residuals were converted to percentages by dividing the residuals 
by the predicted values. We considered MPPE < 5% to be acceptable. Imprecision was 
assessed using median absolute percentage prediction error (MAPE) for which we accepted 
 5
Limited Sampling Strategy for Prolonged-Release Tacrolimus in Renal Transplant Patients by Use of the Dried Blood Spot Technique
88
a percentage limit of <10%. These strict criteria for predictive performance were chosen 
considering the narrow therapeutic index of tacrolimus, for which small changes in total 
exposure could be clinically relevant. This is also reflected in altered European guidelines for 
drug formulation bio-equivalence studies, specifying that for narrow therapeutic index drugs 
the acceptance interval for AUC can be tightened to 90.0–111.1% (16). Niioka et al. recently 
used the same criteria for MPPE and MAPE to evaluate their LSS for prolonged release 
tacrolimus in Japanese renal transplant recipients (17).
All statistical analyses were performed with SPSS for Windows version 20.0 (SPSS Inc, 
Chicago, IL) and R version 2.15.2. P values of below 0.05 were considered significant.
Results
Of the thirty patients who were recruited for the study, 26 patients completed a full 
pharmacokinetic profile. Four exclusions were due to insufficient quality of the blood spots 
(n =1), and giving up informed consent (n=3). All 26 participants had an isolated kidney 
transplantation and were of Caucasian ancestry. Other patient characteristics are shown in 
Table 1.
Table 1 
Patient characteristics (n=26)
Male (%) 69
Caucasian (%) 100
Age (years) 43.9 (36.1-57.6)
Weight (kg) 78.4 (72.6-86.1)
Time after transplantation (years) 5.4 (2.3-7.1)
eGFR (ml/min/1.73m2) 51.5 (40.8-59.3)
Hematocrit 0.39 (0.36-0.41)
Albumin (g/L) 39.5 (36.0-41.0)
Use of calcium channel blockers (%) 58
Use of steroids (%) 77
Data are shown as median with interquartile range
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The median daily dose of prolonged-release tacrolimus was 4.0 mg (range 1.5-10.0). The 
geometric mean C0 and 24-hours post-dose trough level (C24) were 7.7 µg/L (95% confidence 
interval 7.0-8.5) and 8.3 µg/L (7.5-9.1), respectively. The geometric mean AUC0-24 of tacrolimus 
was 288 µg.h/L (262-317). The mean ratio of AUC0-24 and C24 was 34.8 (33.2-36.5). The 
pharmacokinetics of prolonged-release tacrolimus are summarized in Figure 1 and Table 2.
Figure 1
Tacrolimus concentration-time curve
Data are shown as geometric mean with 95% confidence interval
Various sampling time points and combinations of sampling time points were used to construct 
a regression model for the prediction of the AUC0-24. Relatively high adjusted r
2 values, 
approaching 0.90, could already be reached with inclusion of only one sampling time, but 
r2 increased with the inclusion of two or three sampling times. The best performing limited 
sampling strategies for ambulatory patients in the outpatient department, based on one, two, 
or three time points within 4 hours post-dose, are shown in Table 3A. Sampling at 0, 2 and 4 
hours post-dose provided the best prediction of AUC0-24. The adjusted r
2 was 0.95 and MPPE 
and MAPE, measures for bias and precision of the prediction formulas, were 0.4% and 4.8%, 
respectively. For patients who performed home-based measurements (sampling allowed up to 
12 h post-dose), an equation with sampling times at 2, 8 and 12 hours post-dose revealed the 
best results. The adjusted r2 was 0.98 and MPPE and MAPE were 0.4% and 2.8%, respectively 
(Table 3B).
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Table 2 
Pharmacokinetic parameters (n=26)
AUC(0-24) (µg.h/L) 288 (262-317)
Cmax (µg/L) 22.1 (19.4-25.2)
Tmax (h) 2.0 (1.0-4.1)
T½ (h) 29.4 (26.3-33.0)
Cl/F (L/h) 15.2 (12.9-18.0)
Vd/F (L) 647(545-768)
Data are shown as geometric mean (95% confidence interval) except in the case of Tmax, which is shown as median 
and range. Cmax: maximal concentration; AUC(0-24): area under the curve in a 24 hours period; Tmax: time for reaching 
Cmax; T½: elimination half time; Cl/F: apparent clearance; Vd/F: apparent volume of distribution. Intake of prolonged-release 
tacrolimus was on an empty stomach.  
Table 3
Best performing one, two and three sampling strategies for estimation of AUC(0-24) of prolonged-
release tacrolimus for A) sampling up to 4 hours allowed, and B) sampling up to 12 hours allowed
A
Sampling times Equation Adjusted R2 MPPE % MAPE %
T4 AUC(0-24) = 107.6 + 10.6xC4 0.89 -0.25 5.73
T0,T4 AUC(0-24) = 57.5 + 10.1xC0 + 8.9xC4 0.93 0.45 5.27
T0,T2,T4 AUC(0-24) = 44.9 + 8.9xC0 + 2.1x C2 + 7.6xC4 0.95 0.38 4.80
B
Sampling times Equation Adjusted R2 MPPE % MAPE %
T8 AUC(0-24) = 37.6 + 20.6xC8 0.89 1.23 5.21
T8,T12 AUC(0-24) = -8.8 + 11.8xC8 + 14.2xC12 0.96 -0.28 4.71
T2,T8,T12 AUC(0-24) = -12.8 + 2.1xC2 + 9.7x C8 + 12.7xC12 0.98 -0.38 2.82
Abbreviations: MPPE: median percentage prediction error; MAPE: median absolute prediction error; AUC(0-24): area under 
the curve in a 24 hours period. The equations were developed for Caucasian kidney transplant recipients who took prolonged-
release tacrolimus on an empty stomach.
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The commonly used trough level (C24) to predict exposure to prolonged-release tacrolimus 
provided an adjusted r2 of 0.77 with AUC0-24. MPPE and MAPE of C24 were 6.2% and 7.2%, 
respectively. The strongest correlation between a single measurement and AUC0-24 was found 
for C8 (adjusted r
2 = 0.89) while MPPE and MAPE in this case were 1.2% and 5.2% (Table 3B). 
No relevant effect of hematocrit and co-administration of steroids and calcium channel 
blockers (CCBs) on adjusted r2 and predictive performances of the prediction formulas with 
sampling at 0, 2, and 4 hours or at 2, 8 and 12 hours post-dose was apparent (Table 4). 
Table 4
Predictive performance of the equations in subgroups
Sampling T0,T2,T4 Sampling at T2,T8,T12
MPPE MAPE MPPE MAPE
Steroids using (n=20) -1.2% 4.3% 1.3% 2.4%
not using (n=6) 2.5% 4.7% -3.0% 2.9%
CCBs using (n=15) -0.4% 5.0% 1.3% 2.7%
non using (n=11) -0.3% 3.6% -1.1% 2.4%
Abbreviations: MPPE: median percentage prediction error; MAPE: median absolute prediction error;  
CCBs: calcium channel blockers.
Discussion
In this study, we developed equations to estimate AUC0-24 of prolonged-release tacrolimus 
which are clinically applicable for ambulatory Caucasian renal transplant patients. These 
strategies enclose up to three sampling time points and provide an accurate and precise 
estimation of the AUC0-24.
In daily clinical practice, the trough level (C24) of prolonged-release tacrolimus is commonly 
used to establish whether exposure is adequate. The dose of prolonged-release tacrolimus 
is adjusted if C24 is outside the defined target range. According to most studies, there is 
a moderate to high correlation between trough level and exposure to prolonged-release 
tacrolimus (2, 6-9). In fact, r2 of 0.77 in the current study confirms this correlation. However, 
concerns have been raised that this degree of correlation is not sufficient since correlation is 
not a good measure for predictive performance (10). It should be better evaluated in terms of 
bias and precision, which are expressed as MPPE and MAPE, respectively (12, 18). Criteria 
for MPPE and MAPE are somewhat arbitrary and maximum values of 15-20% have been 
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suggested before (12). However, these limits are not strict enough for a drug with a narrow 
therapeutic index. In agreement with Niioka et al. we chose to use 5% and 10% as cut-off 
values for acceptable MPPE and MAPE (17). According to these criteria, the prediction of 
AUC0-24 based on trough levels was biased (yet precise). Interestingly, Scholten et al. showed 
that overexposure to tacrolimus in patients using the regular formulation was less frequent 
when dosing was based on AUC measurements as compared to trough levels only (11). 
Although this has not been demonstrated for the prolonged-release formulation of tacrolimus, it 
is likely that the same holds true here since the correlation between trough levels and AUC are 
about the same for either formulation. 
The two main approaches for developing LLS are multiple linear regression and Bayesian 
analysis. They are equally valid but have different advantages and disadvantages (12). 
We preferred multiple regression analysis as it is relatively simple to develop, to use, and 
to incorporate in clinical practice. The regression analyses are conceptually clear and this 
approach is not dependent on knowledge or assumptions on the pharmacokinetics of the 
drug and the choice of a specific pharmacokinetic model. Once equations are obtained, AUC 
values can be estimated by straightforward calculations that can even be done manually. 
Disadvantages are that only limited deviation from target sampling times is allowed and that 
the LSS is only applicable for patients with similar characteristics as for whom the strategy was 
developed. Our LSS is therefore only applicable in Caucasian patients who take prolonged-
release tacrolimus on an empty stomach as recommended in the product information. The 
Bayesian forecasting method uses population pharmacokinetic data, drug dosing information, 
and measured concentrations to estimate pharmacokinetic parameters of the individual 
patient. Advantages of Bayesian forecasting combined with limited sampling are flexibility 
with sampling times, and simultaneous prediction of several pharmacokinetic parameters. 
Moreover, the LSS can continuously be updated by incorporating new data into the population 
data set. However, the Bayesian strategy also requires expertise with specific software and a 
choice for a pharmacokinetic model of the drug that affects the predictive performance of the 
LSS. Furthermore, users need extensive training in operating the programs and interpreting 
the results, and Bayesian analysis demands for rather extensive data entry which may not be 
feasible in daily clinical practice.
In our study, we did not prospectively validate our limited sampling formulas. Alternatively, we 
computed residuals for every patient in a model which fitted to a dataset where that patient 
was omitted. This analysis is a useful and appropriate approach if the sample size is small (12). 
Differences in pharmacokinetics of tacrolimus are partly explained by genetic polymorphisms 
of CYP3A5 (19). Moreover, co-medication as steroids and CCBs affect the pharmacokinetics 
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of this drug. Therefore, it is important to determine whether bias and precision in the several 
prediction formulas are affected by CYP3A5 polymorphism or use of co-medication. We 
showed that CYP3A5 polymorphisms and co-medication did not significantly influence the 
performances of the prediction formulas. Niioka et al. previously showed that in their developed 
LSS, the effect of CYP3A5 polymorphism was also irrelevant (17).
One LSS using multiple linear regression and three limited sampling strategies by use of the 
Bayesian forecasting method have currently been published for prolonged-release tacrolimus 
in adult renal transplant patients (10, 17, 20, 21). The LSS for prolonged-release tacrolimus 
which used multiple regression was described by Niioka et al (17). Their LSS was developed 
in Japanese patients while our LSS is applicable for Caucasian patients. Moreover, they 
used the chemiluminescence magnetic micro particle immunoassay on the Architect-i1000 
system (Abbott Laboratories; Abbott Park, IL) for bio-analysis of tacrolimus, whereas we used 
the highly specific HPLC-MS/MS method which does not measure crossreacting inactive 
tacrolimus metabolites (22-24). For limited sampling during a period of 4 hours, they also 
found 0, 2 and 4 hours post-dose as optimal sampling strategy. However, the correlation 
between predicted and observed AUC0-24 appeared higher  (r
2 0.95 versus 0.85) and precision 
appeared better (MAPE 4.8% versus 9.8%) with our formula. Their LSS for home-based 
measurements contained 3 sampling time points at 0, 3 and 12 hours post-dose, compared 
to 2, 8 and 12 hours post-dose in our study. The correlation and predictive performances 
appeared comparable. The limited sampling strategies using the Bayesian forecasting method 
all enclosed sampling at 0, 1 and 3 hours post-dose (10, 20, 21).
For this study we used the innovative ‘dried blood spot’ technique which has proven to be 
very reliable for determining tacrolimus levels (14). This technique requires careful training 
of the patients involved, but then obviates the need for hospital visits, phlebotomies, and 
clinical research facilities. Therefore this technique seems very suitable for observational 
pharmacokinetic studies in a home-based, day-to-day clinical setting (4). In routine clinical 
care, the dried blood spot technique can also used for a selected group of patients who can 
be taught well and are able to execute it. Therefore, we also developed prediction formulas in 
which the time span of LSS is less relevant. 
Finally, the AUC of tacrolimus is considered to be a better measure for exposure than the 
trough level (5). However, it has not been proven that AUC-based TDM resulted in a better graft 
or patient survival than trough level-based TDM (5). Moreover, the target AUC of tacrolimus 
for patients who are more than 6 months after renal transplantation has to be established. 
Additional prospective trials with large patient numbers would therefore be needed to assess 
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the effects of using AUC versus trough level on outcome and to determine the target AUC. 
We would especially be interested in studies with patients for whom a better estimation of the 
exposure to tacrolimus is critical, like highly immunized patients or patients with calcineurin 
inhibitor nephrotoxicity.
In conclusion, a LSS using samples collected before the intake and at 2 and 4 hours post-dose 
can be applied for a very accurate and precise estimation of the AUC0-24 of prolonged-release 
tacrolimus in ambulatory renal transplant patients. A LSS with samples obtained before the 
intake and at 3 and 12 hours also showed a good predictive performance but it seems only 
suitable for patients who can execute the dried blood spot measurement at home.
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Abstract
Background: Trough concentrations of prolonged-release tacrolimus are usually measured 
at 24 hours after taking the drug in the morning. It is impractical to measure these trough 
concentrations in patients who visit the outpatient clinic in the afternoon. Trough concentrations 
obtained in the afternoon may also be suitable for estimating the 24-hour exposure. We 
therefore aimed to assess the usefulness of tacrolimus concentrations measured at 32 hours 
post-dose for therapeutic drug monitoring in renal transplant patients who take prolonged-
release tacrolimus.
Methods: We measured tacrolimus pharmacokinetics in 26 patients using prolonged-release 
tacrolimus. Eleven blood samples were taken during a period of 32 hours after ingestion by 
use of a validated dried blood spot method. Tacrolimus concentrations were measured with 
HPLC-tandem mass spectrometry.
Results: The mean concentrations at 24 and 32 hours post-dose were 8.3 µg/L (7.5-9.1) and 
6.7 µg/L (6.1-7.4), respectively (p<0.0001). The Spearman correlation coefficients between 
these concentrations and 24-hour exposure were 0.83 and 0.82, respectively (both p<0.01). 
Conclusions: Delayed trough level measurement provides lower values and therefore requires 
adjustment of the target range. However, levels measured until 32 hours after ingestion remain 
strongly correlated with 24-hour exposure. This warrants the use of delayed trough level 
measurement to improve patient convenience.
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Introduction
Tacrolimus is an important component of the current immunosuppressive therapy after renal 
transplantation. While it was developed as an oral twice-daily formulation, a prolonged-release 
once-daily formulation was introduced on the market in 2007. A recently published systematic 
review indicated that the efficacy of prolonged-release tacrolimus is comparable to that of the 
twice-daily formulation (1). The nature and incidence of adverse effects do not differ either (2). 
Kuijpers et al. lately demonstrated that the once-daily administration of tacrolimus improves 
adherence, which might ultimately contribute to a better graft outcome (3).
Tacrolimus has a narrow therapeutic window and is characterized by a wide inter-individual 
variability in its pharmacokinetics, which is partly explained by genetic polymorphisms of the 
CYP3A isoenzymes and efflux pumps. Moreover, co-medication, hematocrit and albumin, 
patient age and race, gastrointestinal motility, time after transplantation, and liver function can 
all affect the pharmacokinetics of this drug (4). Because of the narrow therapeutic window and 
high inter-patient pharmacokinetic variability, therapeutic drug monitoring (TDM) is indicated for 
tacrolimus. It is usually based on measurement of the trough level, which is reasonably good 
correlated with the total exposure as reflected by the area under the concentration-time curve 
(AUC) (5, 6).
According to the instructions of the manufacturer, blood samples for the trough level of 
prolonged-release tacrolimus should be obtained in the morning, approximately 24 hours after 
the ingestion. Since the apparent elimination half-life of the prolonged-release formulation 
is relatively long (7, 8), the interval between ingestion and blood sampling for trough level 
measurement might be extended beyond 24 hours. In daily clinical practice, a widened 
timeframe for sample collection to measure the trough level would especially be desirable and 
convenient for patients who visit the outpatient clinic in the afternoon. 
The current study aimed to describe the course of the tacrolimus blood concentration between 
24 hours (C24) and 32 hours (C32) after ingestion of prolonged-release tacrolimus. More 
specifically, we assessed whether the degree of correlation between C32 and AUC in a 24-hours 
period (AUC(0-24h)) equaled that of between C24 and AUC(0-24h).
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Patients and methods
Study design and population
We performed a prospective pharmacokinetic study to measure the tacrolimus concentration 
during a period of 32 hours after ingestion of prolonged-release tacrolimus in the morning.
Adult renal transplant patients with a stable graft function were eligible for enrolment if they 
used prolonged-release tacrolimus (Advagraf®) of which the dose was not altered during the 
last visit to the outpatient clinic. Moreover, the two most recently measured trough levels should 
be within the target range of 5-10 µg/L. Patients were excluded if they were unable to perform 
the home based dried blood spot measurements of tacrolimus levels (see below). Patients with 
diarrhea (more than 3 stools per day) during the preceding 14 days were also excluded, since 
diarrhea can affect the pharmacokinetics of tacrolimus (9).
The study was approved by the local ethics committee and conducted in accordance with the 
Helsinki as well as the Istanbul Declaration. All patients gave written informed consent.
Measurements
A validated dried blood spot method for sampling and analysis of tacrolimus was used, which 
allowed participants to take their own blood samples at home (10). Using this method, capillary 
blood is obtained by a finger prick with an automatic lancet by the patients themselves. 
Subsequently, the drop of blood is applied to the sampling paper. After drying and transport of 
the paper to the laboratory, a disk from the blood spot is punched out, extracted and analyzed 
by high-performance liquid chromatography-tandem mass spectrometry. Values obtained with 
the dried blood spot technique show an excellent correlation (r2=0.96) with those obtained 
from venous blood sampling, with a limited difference between both methods (11). Participants 
received thorough training in using the dried blood spot method prior to performing the 
pharmacokinetic measurements. Each pharmacokinetic profile started with measurement of 
the whole blood tacrolimus concentration (C0) at 24 hours after the previous morning ingestion 
of prolonged-release tacrolimus and after overnight fasting. Subsequently, prolonged-release 
tacrolimus was taken and blood samples were collected at 1, 2, 4, 8, 12, 24, 26, 28, 30, and 
32 hours after the ingestion. The participants took prolonged-release tacrolimus on an empty 
stomach and refrained from food intake until two hours after drug ingestion since it has been 
reported that the tacrolimus concentration profile can be influenced by meal consumption (12). 
Pharmacokinetic parameters were assessed with noncompartmental methods. C0 and 
concentrations at 24, 26, 28, 30 and 32 hours post-dose were read directly from the 
pharmacokinetic profile. The AUC(0-24h) was calculated by the linear-log trapezoidal rule.
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Statistical analysis
Pharmacokinetic parameters and concentrations are described with a geometric mean and 
95% confidence interval. Tmax, daily tacrolimus dose, and time after ingestion are presented as 
median and range. The other data are shown as mean with standard deviation (SD).
We primarily focused on the correlation between blood concentrations obtained at various 
time points on the one hand and total exposure as reflected by AUC(0-24h) on the other hand. 
Correlations between blood concentrations measured at 24, 26, 28, 30 or 32 hours after 
drug intake and AUC(0-24h) values were assessed with the non-parametric Spearman’s rank 
correlation coefficient (rho). In addition, we analyzed the difference between blood levels 
measured at 24 and 32 hours after taking tacrolimus, using the paired-samples T-test on 
log-transformed concentration data. A univariate analysis was carried out to identify variables 
affecting the relative difference between C24 and C32 concentrations, with the aim to perform a 
multiple linear regression analysis to evaluate the effect of variables with a p value of less than 
0.1 in univariate analysis.
Because of the explorative character of the study it was difficult to determine the sample size. 
We intended to include approximately 25 patients since this is an acceptable and customary 
number of patients for a descriptive pharmacokinetic study.
All statistical analyses were performed by using SPSS software version 20.0 (SPSS Inc., 
Chicago, IL, USA).
Results
Of the thirty patients who were recruited for the study, 26 patients completed a full 
pharmacokinetic profile. All 26 participants had an isolated kidney transplantation and were of 
Caucasian ancestry. Other patient characteristics are shown in Table 1. 
The median dose of prolonged-release tacrolimus was 4.0 mg (range 1.5-10.0). The geometric 
mean of AUC(0-24h) was 288.1 µg.h/L (261.6-317.3). Geometric means of C24 and C32 were 
8.3 (7.5-9.1) µg/L and 6.7 (6.1-7.4) µg/L, respectively (p<0.0001). Other pharmacokinetic 
parameters and geometric mean concentrations at time points 26, 28, and 30 hours post-dose 
are summarized in Table 2.
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Table 1
Patient characteristics (n=26)
Male (%) 69
Age (years) 46.5 ± 13.4
Weight (kg) 80.0 ± 15.4
Time after transplantation (years) 5.6 ± 3.9
eGFR (ml/min/1.73m2) 49.9 ± 14.5
Hematocrit 0.39 ± 0.05
Albumin (g/L) 38.6 ± 3.2
Use of calcium channel blockers (%) 58
Use of steroids (%) 77
Data are shown as mean with standard deviation
The Spearman’s rank correlation coefficients between single blood levels and AUC(0-24h) were 
0.83, 0.83, 0.84, 0.88 and 0.82 for blood levels taken at 24, 26, 28, 30 and 32 hours post-dose, 
respectively (p<0.01 for each time point). The relationship between AUC and blood levels 
obtained after 24 and 32 hours in individual subjects is depicted in Figure 1. The coefficients of 
variation of the ratios between AUC(0-24h) and C24 or C32 were 13.2% and 12.1%, respectively.
The median relative difference between the blood levels obtained after 24 and 32 hours was 
18.7% (range 35.4% to 14.8%). The median relative differences between blood concentrations 
at 24 hours post-dose and at 26, 28 and 30 hours post-dose were -6.7% (-26.1% to 29.5%), 
-9.5% (-28.3% to 39.4%) and -14.1% (-28.3% to 0.0%), respectively. The relative change in 
concentration between 24 and 32 hours post-dose showed no correlation with the absolute 
mean trough level (Figure 2). The relative difference between C24 and C32 was also not 
significantly associated with age, weight, time after transplantation, hematocrit, albumin, 
creatinine, estimated glomerular filtration rate, or use of steroids and calcium channel blockers. 
As univariate analyses revealed no possible predictors of the percent difference between C24 
and C32, no multivariate analysis was performed.
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Table 2 
Pharmacokinetic data for tacrolimus administered once-daily in a prolonged-release formulation 
(n=26) 
AUC(0-24h) (µg.h/L) 288.1 (261.6-317.3)
C0 (µg/L) 7.7 (7.0-8.5)
Cmax (µg/L) 22.1 (19.4-25.2)
Tmax (h) 2.0 (1.0-4.1)
C24 (µg/L) 8.3 (7.5-9.1)
C26 (µg/L) 7.8 (7.1-8.6)
C28 (µg/L) 7.5 (6.8-8.3)
C30 (µg/L) 7.1 (6.4-7.9)
C32 (µg/L) 6.7 (6.1-7.4)
T½ (h) 29.4 (26.3-33.0)
Data are shown as geometric mean (95% confidence interval) except in the case of Tmax, which is shown as median and 
range. AUC(0-24h): area under the curve in a 24-hours period; C0: pre-dose trough level; Cmax: maximal concentration; 
Tmax: time for reaching Cmax; C24: level after 24 hours; C26:  level after 26 hours; C28:  level after 28 hours; C30:  level 
after 30 hours: C32: level after 32 hours; T½: elimination half time
Discussion
To our knowledge, this is the first prospective study to assess the pharmacokinetics of 
prolonged-release tacrolimus beyond 24 hours after its intake in solid organ transplant 
recipients. We showed that AUC(0-24h) was strongly correlated to the blood concentration at all 
time points measured between 24 and 32 hours post-dose. The collection of the blood sample 
to measure the trough level can therefore be postponed until 32 hours after ingestion for the 
purpose of TDM of prolonged-release tacrolimus. For daily clinical practice, this provides the 
opportunity for ambulatory patients to visit the outpatient clinic, with measurement of the trough 
level, in the afternoon. However, adjustment of the target range is required if C32 is used for 
TDM since there was a significant difference between blood levels obtained at 24 and 32 hours 
after ingestion. The average concentration at 32 hours post-dose was approximately 19% lower 
than at 24 hours. 
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Prolonged-release tacrolimus was developed by adding a combination of ethylcellulose, 
hypromellose and lactose monohydrate to tacrolimus (2). Of these, ethylcellulose changes 
drug release by controlling water penetration and hypromellose affects drug release by forming 
a protective polymer gel layer around the drug. Consequently, tacrolimus once-daily is slowly 
released along the gastrointestinal tract which has been shown to delay Tmax and reduce Cmax in 
stable renal transplant recipients (2, 6).
Tacrolimus trough levels are commonly used as marker for the exposure since it is not 
practically feasible in daily clinical practice to perform a pharmacokinetic profile. The correlation 
between trough level and AUC(0-24h) is high and similar for the prolonged-release  and the 
regular formulation of tacrolimus (5, 6). In this study, we showed that also beyond 24 hours 
after the intake of prolonged-release tacrolimus the correlation between trough level and AUC(0-
24h) remains equally high. Moreover, the coefficients of variation of the ratios between AUC(0-24h) 
and C24 and between AUC(0-24h) and C32 are comparable. An average decline in tacrolimus 
concentrations occurred from 24 to 32 hours post-dose, but differences between tacrolimus 
concentrations at 24 and 32 hours post-dose varied from a rise of 15% to a decline of 35% 
in individual patients. These differences show that despite a high correlation between blood 
concentrations at 24 hours or 32 hours post-dose and AUC(0-24h) wide inter-patient variability 
of the shape of the tacrolimus concentration time curve exists. Hence, similar concentrations 
measured at 24 hours or 32 hours represent a range of AUC(0-24h) in individual patients and this 
variability should be considered if these blood concentrations are assessed.
According to the manufacturer, the elimination half-life of prolonged release tacrolimus in 
healthy volunteers is approximately 43 hours. In our study, we found an average apparent 
elimination half-life of 29.4 hours, much less than 43 hours. It should be noted that the 
observation period of 32 hours is too short for accurate estimation of such a long elimination 
half-life, yet the difference with the elimination half-life data found in healthy volunteers 
appeared to be rather large. This discrepancy between healthy volunteers and renal transplant 
patients has also been observed in users of tacrolimus twice-daily (4). Potential explanations 
for this difference are enzyme induction by use of steroids and a lower hematocrit and albumin 
concentration, resulting in a larger free fraction of tacrolimus, in renal transplant recipients (4, 
13).
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Figure 1 
Correlation between 24-hours area under the curve (AUC0-24h) and tacrolimus blood concentration.
A: tacrolimus blood concentration at 24 hours after ingestion. B: tacrolimus blood concentration at 32 hours after ingestion. 
Correlation coefficients relate to Spearman’s rho.
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Figure 2 
Bland-Altman plot of percent difference between tacrolimus concentrations at 24 hours and 32 hours 
post-dose versus the mean blood concentration.
Parameters that can influence the pharmacokinetics of the tacrolimus twice-daily formulation 
include co-medication, hematocrit and albumin, patient age and race, gastrointestinal 
motility, time after transplantation, and genetic polymorphisms of the CYP3A isoenzymes 
and P-glycoprotein pump (4). The same parameters could also affect the pharmacokinetics 
of the prolonged-release formulation since the active constituent of both preparations is 
identical. Nevertheless, we found no significant effect of age, weight, time after transplantation, 
hematocrit, albumin, and use of steroids and calcium channel blockers on the decrease in 
tacrolimus blood levels between 24 and 32 hours after ingestion.
TDM for prolonged-release tacrolimus is usually performed by measuring the trough level as 
a reflection of total exposure. In agreement with several other studies we showed a strong 
correlation between trough level and AUC(0-24h)  in renal transplant patients (r>0.80) (6, 14).
Using the C32 (or another concentration measured beyond 24 hours after the dose) for 
TDM offers a practical solution for ambulatory patients who visit the outpatient clinic in the 
afternoon. This strategy implies that on the day of examination patients take their prolonged-
release tacrolimus dose in the afternoon (after collection of the blood sample). The occasional 
prolongation of the dosing interval with eight hours appears to be safe since the C32 is on 
average only 19% lower than the C24. Clearly, the target range requires adjustment for late 
tacrolimus measurements and this adjustment can be calculated straightforward based 
on the average decline of tacrolimus concentrations beyond 24 h after the dose (Table 2). 
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Alternatively, the data from this study (i.e. population pharmacokinetic data, Table 2) can 
be used to build a Bayesian forecasting model. In such a model, the “a priori” population 
pharmacokinetic parameters, the patient’s drug dosing information and measured blood 
concentrations are used to assess “a posteriori” pharmacokinetic parameters. Use of the 
Bayesian approach offers more flexibility regarding time point of measurement, but it requires 
expertise with specific software. A pharmacist or clinical pharmacologist has to be involved if 
using the Bayesian approach. Another alternative option for patients who visit the outpatient 
clinic in the afternoon, is to use the dried blood spot test for sampling in the morning at home. 
However, this technique requires careful training and is not suitable for every patient. Finally, 
delay of the intake of prolonged-release tacrolimus at the day before the office visit to 24 hours 
before blood sampling is not a good alternative since tacrolimus pharmacokinetics is affected 
by diurnal variations. In healthy volunteers, administration of prolonged-release tacrolimus in 
the evening reduced the AUC(0-24h) by 35% as compared by intake in the morning (5).
In conclusion, delayed trough level measurement during use of prolonged-release tacrolimus 
formulation provides a good estimate of the AUC(0-24h), although  the target range has to be 
lowered. This allows planning visits to the outpatient clinic with blood sampling for measuring 
the tacrolimus trough level in the morning as well as in the afternoon.
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Abstract
Background: Adherence to the immunosuppressive therapy, which is important to prevent 
rejection after organ transplantation, is influenced by satisfaction of patients with their 
medication regimen. The aim was to investigate the effect of introducing a simplified 
medication regimen for renal transplant patients on treatment satisfaction, in particular 
convenience.
Methods: In a prospective cohort study treatment was switched from tacrolimus twice-daily to 
tacrolimus once-daily with a simultaneous change to a once-daily formulation of other drugs if 
applicable. Treatment satisfaction was measured in 75 participants with the validated Treatment 
Satisfaction Questionnaire for Medication (TSQM) version II. 
Results: The treatment convenience score increased from 66.0 (standard deviation 14.5) to 
78.5 (14.5) (p<0.001). The daily number of medication ingestion time points diminished from 
2.4 (0.7) to 1.6 (0.7) (p<0.001) and the daily number of tablets decreased from 12.4 (3.3) to 9.1 
(2.6) (p<0.001). The self-reported adherence to the medication regimen increased from 79.7% 
to 94.6% (p<0.001). 
Conclusion: The introduction of a simplified medication regimen enabled by the use of a once-
daily formulation of tacrolimus increases treatment convenience after renal transplantation. This 
regimen had a beneficial effect on self-reported adherence.
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Introduction
Non-adherence to medication is a serious health concern among renal transplant recipients. 
Review papers describe that the prevalence of non-adherence to immunosuppressive therapy 
is about 25% (1, 2). It has been estimated that non-adherence contributes to 20% of late acute 
rejection episodes and 16-36% of graft losses, with a seven-fold increased risk of graft loss in 
non-adherent as compared with adherent patients (1, 2). The percentage of kidney transplant 
patients who are not adherent is higher than in recipients of other solid organs, possibly 
because of the non vital nature of the renal graft (3). In addition, the adherence to the non-
immunosuppressive treatment is lower than to immunosuppressive drug therapy (4, 5).
A complex medication regimen is one of the risk factors for non-adherence (6). Evidence from 
several fields of pharmacotherapy shows that simplification of the drug regimen leads to a 
better adherence (7-9).
In the past, the use of calcineurin inhibitors prohibited simplification of the medication regimen 
in many renal transplant recipients due to the fact that tacrolimus and cyclosporine had to be 
taken twice daily. A modified-release formulation of tacrolimus which can be taken once daily 
was approved for use in Europe in 2007. A recently published systematic review indicates that 
the efficacy of tacrolimus once-daily is comparable to that of the twice-daily formulation (10). 
The frequency and type of side effects did not differ as well (11).
Most tacrolimus-treated renal transplant patients use several other drugs like other 
immunosuppressive agents and antihypertensive drugs. The conversion from the twice-daily to 
the once-daily formulation of tacrolimus will especially be beneficial in case the concomitantly 
used drugs can be prescribed in a once-daily formulation as well. Simplification of the entire drug 
regimen can enable patients to take drugs at one or two convenient time points per day, e.g. 
early in the morning and at bedtime. It permits patients to remain free of drug intake during work 
or social activities. Such a simplified medication regimen might improve treatment satisfaction 
and thereby enhance medication adherence. A validated questionnaire has been developed to 
measure treatment satisfaction (12). Atkinson et al. showed with this questionnaire that treatment 
satisfaction and especially treatment convenience is correlated with medication adherence (12).
Hence, our study aimed to investigate the effect of introducing a simplified medication 
regimen in tacrolimus-treated renal transplant patients on treatment satisfaction, in particular 
convenience. In addition, we studied the effect of simplification on the self-reported adherence. 
Finally, we aimed to quantify the proportion of an unselected cohort of tacrolimus-treated renal 
transplant recipients that would be eligible for a simplified drug regimen.
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Patients and methods 
Study design
We performed a prospective cohort study to investigate the effect of introducing a simplified 
drug regimen on treatment satisfaction, in particular convenience. A simplified medication 
regimen was defined as a regimen in which every drug is prescribed in a once-daily 
preparation, enabling to limit drug intake to one or two convenient time points per day (e.g. 
early in the morning and/or at bedtime). Although exclusively once-daily preparations were 
used, two ingestion times per day were allowed since some drugs required to be taken on 
specific time points for optimal effectiveness. Measurements of treatment satisfaction (see 
below) were performed immediately before introduction of the simplified regimen and three 
weeks afterwards (Figure 1). In a random subgroup of patients, we performed the same 
measurements three weeks prior to the introduction of the simplified medication regimen in 
order to assess the potential effects of participation in a study and repeated measuring on the 
outcome parameters. This subgroup was composed of patients within the study population 
with an odd hospital-specific sequence number of renal transplantation. All patients were 
followed during 6 months after introduction of the simplified regimen to check whether adverse 
events occurred.
Moreover, we carried out a cross-sectional review of the records of all patients who underwent 
renal transplantation in our hospital between August 2006 and July 2010 to assess the 
proportion of these patients that could be treated with a simplified medication regimen 
including tacrolimus once-daily.
Study population
Adult renal transplant patients with a stable renal function were eligible for enrolment in the 
conversion study if they used tacrolimus twice-daily in an unchanged dose in the preceding 
three months with a trough level within the target range of 5-10 µg/L. An additional inclusion 
criterion was that every other drug that the patient used, could be taken once daily. In 
some cases it was necessary to change the regular formulation of a drug to a slow-release 
formulation in order to meet this inclusion criterion. In our centre patients typically use triple 
therapy consisting of tacrolimus, steroids, and mycophenolate mofetil during the first six 
months after renal transplantation. 
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Figure 1
Study design
Participants completed questionnaires before introduction of the simplified regimen and three weeks afterwards. In a 
subgroup of patients with an odd hospital specific sequence number of renal transplantation, a questionnaire was also 
completed 3 weeks prior to the introduction of the simplified medication regimen.
Afterwards, we usually taper the dose of mycophenolate mofetil or steroids to zero during a 
period of 6-12 weeks. Since mycophenolate mofetil has to be used twice daily, patients who 
used this drug were not eligible. Hence, participants in our study were at least 7.5 months after 
renal transplantation at time of inclusion. Moreover, patients were excluded if they were unable 
to read and understand the Dutch questionnaire. All patients and their treating physicians 
gave informed consent before participation. The study was conducted in accordance with the 
guidelines of the local ethics committee, the Helsinki Declaration and Istanbul Declaration.
In the cross-sectional review of the records we applied the same in- and exclusion criteria 
except for the language criterion.
Treatment
We converted tacrolimus twice-daily to tacrolimus once-daily (Advagraf®, Astellas Pharma 
Europe Ltd) on a 1:1 (mg:mg) total daily dose basis. Tacrolimus once-daily was taken in the 
morning. Tacrolimus trough levels were measured according to the manufacturer’s guidelines 
between one and two weeks after conversion. If necessary the dose was adjusted to keep the 
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trough level within the target range (5-10 µg/L). We also prescribed all other drugs once-daily 
and changed them to slow-release preparations if indicated. Drugs intake was preferentially 
scheduled in the morning except if the efficacy or mechanism of action of the drug required 
another time point. Statins and sleeping pills were therefore taken just before bedtime. Both the 
tacrolimus once- and twice-daily formulations were provided by the regular pharmacist of the 
patient and reimbursed by the health insurance company.
Measurement methods
Treatment satisfaction was measured by the use of TSQM (Treatment Satisfaction 
Questionnaire for Medication) version II (12). This validated questionnaire is a generic measure 
of treatment satisfaction for medication and includes questions on effectiveness, tolerability, 
convenience, and global satisfaction, generating scores ranging from 0 (extremely dissatisfied) 
to 100 (extremely satisfied). In addition, participants reported their adherence to the medication 
regimen in the previous two weeks, level of education, employment status, work with irregular 
shifts, time spent outdoors, and social support for taking medication (see Appendix). All 
questionnaires were completed at home and returned to the investigator by regular post.
Statistical analysis 
The primary outcome was the change of treatment satisfaction, in particular convenience. 
Secondary outcomes were the changes of self-reported adherence, treatment satisfaction 
regarding presumed effectiveness, global satisfaction and tolerability, and incidence of acute 
rejections within 6 months after conversion.
Based on a power of 0.8, a type I error probability of 0.05, a standard deviation of 14% and an 
absolute difference in primary outcome parameter of 10%, a sample size of 75 participants was 
calculated. 
Normally distributed data are presented as mean with standard deviation (SD) and skewed 
data as median with interquartile range. Data with a skewed distribution were logarithmically 
transformed before analysis. We analysed our data with paired and unpaired T-tests where 
appropriate. A univariate analysis was carried out to identify variables affecting the change in 
convenience score and self-reported adherence. Subsequently, we performed a multivariate 
analysis with linear regression to evaluate the effect of variables with a significance of more 
than 0.1 in univariate analysis. All statistical analyses were performed by using SPSS software 
version 20.0 (SPSS Inc., Chicago, IL, USA).
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Results
Of 82 patients who were invited to participate in our study, 76 gave informed consent and 75 
completed a questionnaire before and after a change in their medication regimen. A subgroup 
consisting of 26 patients also filled out the questionnaire at 3 weeks prior to changing the 
medication regimen. The demographic and clinical characteristics of all participants and the 
subgroup are shown in Table 1. The characteristics of the subgroup were comparable with 
those of the entire group. Tacrolimus twice-daily was converted to the once-daily formulation 
in all patients. Additional prescription changes to achieve a simplified medication regimen 
were made in 41 patients (54.7%). In 11 of these cases (26.9%) this included the substitution 
of metoprolol slow-release for the regular formulation. In other cases it sufficed to take the 
same drugs in a single dose instead of divided doses during the day. The concerning drugs 
were nifedipine (n=8), angiotensin converting enzyme inhibitor (n=10), prednisone (n=23), 
omeprazole (n=1), and losartan (n=1).
The mean cumulative daily tacrolimus dose before and after conversion was 5.0 (2.0) and 5.1 
(2.1) mg, respectively (p=0.32). Ten patients (13.3%) required an increase of the tacrolimus 
dose since their trough level was beneath the target range. Dose reductions were necessary in 
two patients (2.7%). The tacrolimus trough level did not change significantly after conversion: 
6.8 µg/L (1.5) versus 6.7 µg/L (1.8), (p=0.20). 
Three weeks after introduction of the simplified medication regimen, there was a significant 
increase of the mean TSQM convenience score from 66.0 to 78.5 (p<0.001; Table 2). 
The convenience score improved in 64% of the patients. TSQM scores of effectiveness, 
tolerability and global satisfaction did not change significantly. In a subgroup of patients, we 
demonstrated that the TSQM scores did not change in a three week interval prior to changing 
the medication regimen, whereas a similar increase in convenience score was observed 
after simplifying the medication regimen (Table 2). The increase in convenience score did not 
differ between patients with (n=41) or without (n=34) an additional change in the medication 
regimen next to conversion to tacrolimus once-daily: 63.0 to 76.9 versus 69.7 to 80.5 (p=0.50). 
The introduction of the simplified medication regimen resulted in a reduction of the number of 
tablets and capsules from 12.4 (3.3) to 9.1 (2.6) per day (p<0.001). The intake frequency of 
drugs diminished from 2.4 (0.7) to 1.6 (0.7) times per day (p<0.001). Self-reported adherence 
to all drugs during the last two weeks prior to measurement increased from 79.7% to 94.6% 
(p<0.001). The number of missed doses of any drug during that two week period decreased 
from 0.3 (0.1) to 0.1 (0.1) (p<0.01). 
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Table 1 
Patient characteristics
All patients 
(n=75)
Subgroup
(n=26)
p-value
Gender (male) 61.3% 73.1% 0.28
Age (years)* 49.6 (14.1) 49.4 (15.0) 0.97
Race (Caucasian) 94.7% 96.2% 0.76
Donor type (living) 74.7% 73.1% 0.87
Time after transplantation (years)* 3.1 (3.3) 2.6 (1.9) 0.34
Creatinine (µmol/L)* 125.4 (39.1) 130.9 (36.2) 0.53
Tacrolimus trough level (µg/L)* 6.8 (1.5) 6.5 (1.2) 0.88
Concomitant immunosuppressive drugs
-Prednisone
-Azathioprine
-Azathioprine and prednisone
92%
7%
1%
96%
4%
0%
0.80
Employment or study (yes/no/unknown)
Working in shifts (yes/no/unknown)
60%/36%/4%
24%/72%/4%
65%/35%/0%
19%/81%/0%
0.57
0.49
Daily time spent outdoors
- Unknown
- Less than 2 hours
- 2-4 hours
- 4-6 hours
- 6-8 hours
- More than 8 hours
8%
12%
21%
12%
15%
32%
3%
23%
12%
8%
12%
42%
0.53
Education level
- Unknown
- Less than high school
- High-school graduate
- Associate’s degree
- Bachelor’s degree/postgraduate
4%
11%
25%
29%
31%
0%
12%
19%
31%
38%
0.79
*Shown as mean (standard deviation) 
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Patients who reported to be non-adherent in the preceding two weeks to the measurement 
were younger than the adherent patients: 41.5 (16.5) versus 51.5 (12.9) years old (p=0.01). 
Self-reported non-adherence was higher in recipients from a living donor kidney than 
in recipients from a deceased donor kidney (27.3% versus 0%; p=0.01 ). Patients who 
irregularly worked or studied reported more often to be non-adherent (31.1% versus 3.7%; 
p=0.02). The concomitant immunosuppressive therapy more often consisted of prednisone 
than azathioprine in non-adherent patients: 19.4% versus 0% p=0.03). We did not observe 
differences in gender, race, time after transplantation, education level, daily time spent 
outdoors, number of ingestion times, number of tablets and time after transplantation between 
non-adherent and adherent patients. In multivariate analysis however, age, donor type, life style 
and concomitant immunosuppressive therapy did not significantly affect self-reported non-
adherence. 
Table 2
Effects of changing to a simplified medication regimen on the four domains of the Treatment 
Satisfaction Questionnaire for Medication. Measurements were performed three weeks before (T=-3), 
immediately before (T=0), and 3 weeks after (T=3) introduction of the simplified regimen
T=-3 T=0 T=3 p-value
All patients
n=75
Effectiveness 75 (67-83) 75 (67-83) 0.24**
Tolerability 100 (75-100) 100 (83-100) 0.06**
Convenience 66.0 (14.5) 78.5 (14.5) <0.001**
Global satisfaction 72.5 (14.3) 74.4 (14.3) 0.28**
Subgroup
n=26
Effectiveness 75 (67-83) 67 (67-83) 71 (50-83) 0.22* 0.16**
Tolerability 92 (75-100) 100 (73-100) 96 (83-100) 0.93* 0.54**
Convenience 64.8 (14.7) 66.8 (16.3) 77.3 (16.3) 0.50* 0.03**
Global satisfaction 70.8 (15.6) 75.7 (15.4) 76.0 (14.2) 0.08* 0.91**
Effectiveness and tolerability are shown as median (interquartile range); convenience and global satisfaction are shown as 
mean (standard deviation); * p-value of measurement T=-3 versus T=0; ** p-value of measurement T=0 versus T=3
At baseline, the TSQM score of convenience was significantly lower in patients who reported 
to be non-adherent: 60.0 (12.1) vs. 67.8 (14.8) (p=0.04). The increase in convenience score 
was comparable between patients who reported to be non-adherent at baseline and those 
who indicated to be adherent. Nine patients reported to have missed at least one dose of 
tacrolimus in the preceding two weeks prior to changing the regimen, while none of the 
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patients reported to have missed a dose after changing the medication regimen (p<0.01). The 
number of patients who noted that they were reminded by others to take their drugs decreased 
from eight to five (p<0.001). In the subgroup of patients who were assessed thrice (Figure 1), 
we established that the daily number of tablets and capsules, intake frequency, self reported 
adherence, and number of missed drugs did not change in the three week interval prior to 
changing the medication regimen, whereas the changes of these parameters after simplifying 
the medication regimen were similar to that in the entire group of patients (data not shown).
Univariate analysis revealed no significant correlations between the change of the TSQM convenience 
score and age, decrease of drug ingestion times, decrease of the daily number of pills, employment 
status, work with irregular shifts, time spent outdoors, and education level. In multivariate analysis 
however, the decrease of the number of drug ingestion times and age were statistically significant 
covariates of the improvement of convenience score (p<0.01 and p=0.04, respectively). 
Acute rejections or other unexpected side effects were not observed in the first six months 
after change of the medication regimen. We observed no change in blood pressure after 
modification of the antihypertensive regimen (n=27): before modification 132/77 mmHg and 
afterwards 133/79 mmHg (p=0.21). In patients who were converted from twice-daily to once-
daily prednisone (n=23), glucose levels did not change significantly (5.8 versus 5.9 mmol/L; 
p=0.78).
Finally, we evaluated how many of our renal transplant patients might benefit from a simplified 
treatment regimen as described above. Between August 2006 and July 2010, 423 adult 
patients underwent a renal transplantation in our hospital. At the time of evaluation, 368 of 
these patients were alive with a functioning graft. The median time after transplantation of these 
patients was 43 months (range 19 to 67 months) and 231 of these patients used tacrolimus 
twice-daily. In 151 (65%) of these tacrolimus-treated patients it would be feasible to introduce 
a simplified medication regimen including tacrolimus once-daily (in fact, 34 of the study 
participants were recruited from this population). The main reasons for not being eligible for 
a simplified treatment regimen were: concomitant use of mycophenolate mofetil twice-daily 
(n=31), use of one or more antihypertensive drugs that required ingestion twice daily (n=22), 
and use of other drugs that cannot be taken once daily (e.g. phosphate binders; n= 27).
Discussion
Our study showed that simplification of the medication regimen after renal transplantation with 
the use of tacrolimus once-daily and other extended release formulations, resulted in a significant 
A Simplified Medication Regimen Enabled by the Use of Tacrolimus Once-Daily Improves Treatment Satisfaction in Renal Transplant Patients
123
improvement of the treatment convenience measured by a validated questionnaire. Moreover, 
we observed an associated improvement in self-reported drug adherence after simplification 
of the medication regimen. In our clinical practice, more than 65% of an unselected cohort of 
tacrolimus-treated renal transplant patients qualified for the simplified regimen.
Non-adherence threatens the outcome after kidney transplantation and therefore warrants 
serious attention and intervention where possible. Renal transplant patients with a large daily 
number of drug ingestion time points are especially vulnerable to become non-adherent (13). 
The patient’s satisfaction, quality of life, and adherence can improve after reduction of the 
dosing frequency (14). Based on the introduction of a once-daily formulation of tacrolimus, we 
designed a simplified medication regimen, enabling patients to limit their drug intake to one 
or two convenient time points per day (e.g. early in the morning and at bedtime). This allows 
patients to remain free of drug intake during work, outdoor meals, and social activities. The 
observed beneficial effects on treatment satisfaction and adherence were in agreement with 
the results of recently published studies in heart, liver and kidney transplant patients who were 
found to be more adherent after conversion from twice-daily to once-daily tacrolimus (15-18). 
Since it is known that the level of non-adherence to non-immunosuppressive drugs is even 
higher than to immunosuppressive drugs (4, 5), we went one step further than all previously 
published tacrolimus conversion studies by simplifying the entire medication regimen. This 
implied additional changes in the drug regimen in about half of the patients and resulted in an 
average reduction of daily number of drug ingestion time points of 33%. 
An additional strength of our study was the use of a validated questionnaire (TSQM version II) 
for measuring treatment satisfaction. On each domain (effectiveness, tolerability, convenience 
and global satisfaction) of this questionnaire, a score can be generated between 0 and 100%. 
Atkinson et al. showed that from the scores on each of these domains, the score of treatment 
convenience was the best predictor of medication adherence (12). Accordingly, the observed 
rise of treatment convenience in our study was accompanied by a significant decline of non-
adherence. In addition, participants who admitted to be non-adherent had the lowest score on 
treatment convenience.
Previous studies showed that patients who question the effectiveness or importance of their 
medication perceive a lack of autonomy in managing their treatment (19, 20). In addition, 
patients who are anxious about side effects are less likely to take their drugs (8). In our study 
the introduction of the simplified medication regimen did not have a negative impact on the 
experienced effectiveness and side effects, which was not surprising since there was no 
change in the type of drugs.
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The mean number of ingestion times diminished from 2.4 to 1.6 per day. Although all 
prescribed drugs could be taken once daily, a further decrease of the intake frequency was 
not achievable since some drugs should be taken on specific moments (e.g. tacrolimus 
once-daily has to be taken in the morning, while statins are best taken in the evening). The 
reduction of the number of daily ingestion times and age were the only significant covariates 
of the improvement of the convenience score after simplification of the medication regimen. 
Somewhat unexpectedly a number of social circumstances like employment status and 
working in irregular shifts, did not affect the extent to which patients took advantage from a 
simplified medication regimen.
Use of a simplified medication regimen is an important tool to improve treatment satisfaction 
considering the scale on which it could be applied in our clinical practice. The regimen was feasible 
in 65% of the tacrolimus-treated renal transplant recipients. Based on the observed beneficial 
effects of the introduction of a simplified regimen on medication adherence, the number of adherent 
patients might raise with limited efforts. This may ultimately improve graft survival and save financial 
resources, since non-adherence is associated with higher health care costs (21).
According to the manufacturer tacrolimus twice-daily can be converted to tacrolimus once-daily 
in stable renal transplant recipients on a 1:1 (mg:mg) total daily dose basis. Measurements of 
the trough level after conversion are recommended. We have converted our study participants 
successfully by applying these recommendations. Although the pre- and post conversion 
trough level did not differ significantly, 15.0 % of the patients required a dose adjustment upon 
conversion, which is comparable with the data in a recent systematic review (10, 22, 23). In 
contrast, several studies indicated that the use of tacrolimus once-daily was associated with 
lower tacrolimus exposure than initially was assumed (24-26). It was therefore reassuring that 
the conversion policy in our study, including dose adjustment in case of low trough levels, did 
not result in acute rejections in the first six months after introduction of the simplified regimen.
Our study has some limitations. First, we decided not to perform a randomized controlled 
trial because we expected a negative impact of such a design on the willingness to complete 
questionnaires in the control group. Nevertheless, unlike the other observational studies we 
included a subgroup of patients in whom the potential effects of participation in a study and 
repeated measurements on treatment satisfaction and drug taking behaviour were evaluated 
prior to switching the medication regimen. In this surrogate control group there were no 
significant changes before introduction of the simplified regimen, while the magnitude of the 
changes after switching the regimen was similar to that in the entire study population.
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Another limitation of studies like the current one is that only patients who are willing to change 
their medication regimen can participate. Although the number of patients that declined 
participation was relatively small (7%), the included patients might a priori judge more 
positively about the simplified regimen. Therefore, extrapolation of our results to the entire 
tacrolimus-treated patient population might overestimate the effect on treatment convenience.
Since some patients did probably not reveal their true pill-taking behaviour, the self-reported 
measurement might overestimate the true adherence, which was a secondary endpoint in our 
study. However, self-reported measurement has been show to be reliable if the questionnaire is 
completed in a confidential setting as occurred in our study (27).
Finally, the last assessment of treatment satisfaction and self-reported adherence was only 
three weeks after the introduction of the simplified medication regimen and might overestimate 
the long-term effect of the intervention. After disappearance of the novelty of the simplified 
regimen patients could fall back in old habits of being less adherent. We have chosen for the 
current design, since assessment at a later time point would have been more prone for the 
presence of other confounders.
In conclusion, the introduction of a simplified medication regimen based on the use of 
tacrolimus once-daily in renal transplant recipients increases treatment satisfaction with regard 
to convenience. According to the increase of self-reported medication adherence, introduction 
of such a regimen has a beneficial effect on compliance and has the potential to improve long-
term outcome of renal transplantation.
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Supporting information
Additionally to the TSQM, the following questions were used.
(1)   How many times did you forget to take your medication in the last two weeks? (0, 1, 2, 3, 4, 
more than 4 times)
(2) Did you forget to take tacrolimus in the last two weeks? (Yes/No)
(3) Did others remind you to take your medication in the last two weeks? (Yes/No)
(4)  What is your highest level of education? (Less than high school, high-school graduate, 
associate’s degree, bachelor’s degree/postgraduate)
(5) Do you have employment or do you follow a study? (Yes/No)
(6) Do you have irregular shifts at work? (Yes/No)
(7)  How many hours per day do you spend outdoors? (less than 2 h, 2-4 h, 4-6 h, 6-8 h, more 
than 8 h)
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Summary and general discussion
An increased efficacy of immunosuppressive therapy has contributed to the improvement of 
the outcome of renal transplantation over the last decades. Suboptimal immunosuppression 
leads to an increased rate of acute rejections, which can contribute to long-term graft attrition. 
Several factors can jeopardize the efficacy of immunosuppressive treatment and may therefore 
threaten long-term graft survival (1). As a first example, the efficacy may be altered due to 
diseases or disturbances of the gastrointestinal tract. Second, the efficacy of mycophenolate 
mofetil (MMF) might be impaired by the concomitant use of proton pump inhibitors (PPIs). 
Third, impaired adherence to the immunosuppressive regimen is known to increase graft 
attrition rates (2, 3).
Aside from their immunosuppressive action, the drugs that are used to prevent graft rejection 
also have adverse effects outside the immune system. Several of these side effects like 
nephrotoxicity, new onset diabetes after transplantation, hypertension and dyslipidemia can 
have a detrimental effect on long-term graft survival (1). Adequate monitoring of the exposure 
to these drugs is therefore required. 
This thesis focuses on strategies to optimize immunosuppressive therapy, taking into 
consideration the potential shortcomings of current approaches as mentioned above.
Efficacy and adverse effects of immunosuppressive agents and interaction 
with the gastrointestinal tract
In chapter 2, we reviewed the complex interaction between immunosuppressive agents and 
the gastrointestinal tract. Dysfunction and disease of the gastrointestinal tract can affect the 
absorption and metabolism of immunosuppressive drugs. We discussed the consequences 
for the pharmacokinetics of the various immunosuppressive drugs and how to adjust the 
immunosuppressive therapy in patients with disorders of the gastrointestinal tract. Moreover, 
immunosuppressive drugs can cause adverse effects in the gastrointestinal tract and interact 
with drugs, which are often prescribed for gastrointestinal disorders. Knowledge on the 
interplay between immunosuppressive agents and the gastrointestinal tract is required for 
every transplant physician.
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Efficacy of mycophenolate mofetil in combination with proton pump inhibitors
Adequate exposure to mycophenolic acid (MPA), the active metabolite of MMF is associated 
with a decreased rate of acute rejection. It has been shown that PPI, which are commonly 
used post transplantation as prophylaxis against upper gastro-intestinal bleeding, impair the 
exposure to MPA due to incomplete conversion from MMF. In chapter 3, we evaluated the 
effect of the combined use of MMF and the PPI pantoprazole on the risk of biopsy-proven 
acute rejection as compared to the combination of MMF and a histamine 2 (H2) antagonist, 
ranitidine. Of 202 patients who were included in this retrospective study 125 patients used 
pantoprazole and 77 patients used ranitidine. There was no difference in the number of 
patients with biopsy-proven acute rejection (10.4% versus 9.1%). Also after correction for 
inequalities between both groups, the biopsy-proven acute rejection rate did not depend on 
the type of anti-ulcer agent. 
Later on, a retrospective study which addressed the same issue was published (4). In this 
study, 213 patients who used pantoprazole and 384 patients who used ranitidine were 
compared regarding the rate of biopsy proven rejections in the first year after transplantation. 
In contrast to our study, all patients received induction therapy with anti-thymocyte globulin, 
approximately 50% of the patients were of African ancestry, and the donor type was 
predominantly deceased. The investigators confirmed our conclusion that no differences in 
the rate of acute rejection between both groups. However, for certain subgroups of patients, 
those of African ancestry using the combination of MMF and PPI, had an increased risk of 
acute rejection. Other studies also indicated that adequate exposure to MPA is more critical in 
patients of African descent (5, 6). Additionally, patients treated with cyclosporine might form 
another group that is more prone for MPA underexposure as cyclosporine has an inhibitory 
effect on the enterohepatic circulation of MPA. Since we excluded patients treated with 
cyclosporine from our study, we were not able to examine the effect of PPI in these patients. 
Likewise, the proportion of patients who underwent a retransplantation, which is a risk factor for 
rejection, was too small to establish a potential effect of MPA underexposure on the incidence 
of rejection.
The initial effects of H2 receptor antagonists and PPIs on gastric pH are comparable (7, 
8). However, due to tolerance induction, the effect of H2 receptor antagonists on gastric 
pH rapidly wanes during subsequent days, while the effect of PPIs strengthens. Although 
PPIs are therefore considered to provide better peptic ulcer prophylaxis, their superiority is 
never formally established (9, 10). Moreover, long-term use of PPIs may increase the risk of 
hypomagnesemia, bone fractures and Clostridium difficile infection (11), conditions, which also 
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occur as side effects of immunosuppressive drugs. All these are also well known side effects of 
the immunosuppressive regimen after renal transplantation. Therefore, we recommend the use 
of an H2 antagonist as peptic ulcer prophylaxis over a PPI, especially in MMF using patients 
with higher risk of rejection like those of African descent, those treated with cyclosporine, or 
those undergoing a retransplantation. If PPI therapy is required for some reason in these high 
immunological risk patients, e.g. if the risk of gastrointestinal bleeding is increased, measuring 
the exposure to MPA can be advocated. Alternatively, these patients can be treated with 
enteric-coated mycophenolate sodium since the exposure to MPA if using this formulation 
does not seem to be affected by PPI (12).
Tacrolimus nephrotoxicity and mild diarrhea
The nephrotoxicity of the calcineurin inhibitors tacrolimus and cyclosporine is one of the major 
threats for long-term graft function. Therefore, overexposure to these drugs should be avoided 
as much as possible. Severe diarrhea, defined as more than 3 loose stools a day, results in 
increased absorption of tacrolimus, which can substantially increase the trough levels and 
total exposure to the drug (13). While severe diarrhea is exceptional and usually transient, mild 
diarrhea (2-3 stools per day) is more common, particularly in patients who use the combination 
of MMF and tacrolimus (14). Since complaints of mild diarrhea are not always reported to the 
treating physician it can remain unrecognized. For patients with mild diarrhea, it is unclear to 
which extent total exposure to tacrolimus is increased and whether this is reflected by trough 
levels exceeding the target range. A chronic overexposure without a significant increase in 
trough levels might predispose to tacrolimus nephrotoxicity (15). Therefore, we investigated 
the degree of unnoticed tacrolimus overexposure in renal transplant patients with mild 
diarrhea while on treatment with tacrolimus and MMF. The included patients performed two 
full pharmacokinetic profiles to calculate exposure and to establish intra-patient variability. In 
chapter 4, we reported that the area under the concentration versus time curve (AUC0-12) was 
comparable in patients with mild diarrhea versus patients without diarrhea. The mean ratio 
between AUC0-12 and trough level was not significantly different in both groups: 19.2 (95% 
confidence interval 17.5-21.1) versus 20.6 (19.0-22.4). The mean daily dose of tacrolimus did 
not differ significantly either: 6.0 mg (standard deviation 3.3) in patients with mild diarrhea and 
7.1 mg (3.6) in the controls. We could not demonstrate hidden overexposure to tacrolimus 
in renal transplant patients with mild diarrhea. In addition, we concluded that trough level 
measurement in whole blood (rather than recording a full pharmacokinetic profile) suffices for 
detecting tacrolimus overexposure in patients with mild diarrhea. 
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While a relationship between toxicity and high trough levels of tacrolimus was demonstrated 
in some studies (16, 17), evidence accumulates that local renal exposure to tacrolimus or its 
metabolites may be more relevant than systemic drug levels in the development of chronic 
nephrotoxicity (18). The intrarenal concentration of tacrolimus and its primary metabolites 
depends on intrarenal ABCB1 efflux pumps and CYP3A isoenzymes (19). Variability in 
expression and function of these efflux pumps and isoenzymes can explain differences in 
intrarenal tacrolimus levels and nephrotoxicity. It was already shown that the expression of 
ABCB1 in renal allografts with signs of tacrolimus nephrotoxicity is decreased compared 
to grafts without histological damage (20, 21). The relation between activity of CYP3A5, the 
predominant CYP3A enzyme in the kidney, and tacrolimus nephrotoxicity is less clear with 
conflicting results from different studies (22, 23). 
In addition to the intrarenal concentration of tacrolimus and its primary metabolites, several 
factors that increase the susceptibility for tacrolimus nephrotoxicity are currently identified. The 
age of the donor, use of nonsteroidal anti-inflammatory drugs, salt depletion with activation 
of the renin angiotensin system, and polymorphisms of genes involved in the pathogenesis 
of tacrolimus toxicity can all contribute to the development of nephrotoxicity (18). The exact 
pathogenesis has not been elucidated yet and effective means for therapy or prevention of 
tacrolimus nephrotoxicity are currently lacking.
Besides an overall increase in exposure to tacrolimus, mild diarrhea might also result in increased 
intra-patient variability in tacrolimus blood levels. Intra-patient variability in the pharmacokinetics 
of a drug is defined as the amount of fluctuation in drug concentration within an individual over 
a certain time during which the dose is unchanged. A high intra-patient variability in tacrolimus 
exposure is a risk factor for rejection and long-term treatment failure (24, 25). In chapter 4, we 
did not find evidence for an increased intra-patient variability in exposure to tacrolimus in patients 
with mild diarrhea. The absence of wide intra-patient variability is likely explained by the stable 
presence of mild diarrhea with relatively constant absorption. 
Prolonged-release tacrolimus
Tacrolimus was initially developed as an oral twice-daily formulation, but a prolonged-release 
formulation of tacrolimus was introduced more recently. A combination of ethylcellulose, 
hypromellose and lactose monohydrate was added to tacrolimus (26). Ethylcellulose changes 
drug release by controlling water penetration and hypromellose affects drug release by forming 
a protective polymer gel layer around the capsule. Consequently, tacrolimus slowly leaves 
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the prolonged-release capsules along the gastrointestinal tract (26, 27). A systematic review 
concluded that the efficacy of prolonged-release tacrolimus is comparable to that of the 
twice-daily formulation (28). The safety profile does not differ either and its use decreases the 
intra-patient variability (26, 29, 30). Several practical aspects of this prolonged-release formulation 
were addressed in chapters 5, 6 and 7. The first two chapters dealt with a better and more 
convenient estimation of the exposure to prolonged-release tacrolimus. The last chapter focused 
on improving treatment satisfaction by simplification of the immunosuppressive regimen.
Although not always a clear blood concentration-response curve has been shown for 
tacrolimus, therapeutic drug monitoring (TDM) is indicated since it can prevent tacrolimus 
overexposure and decreases the intra-patient variability (31, 32). A consortium of European 
experts on the pharmacokinetics of tacrolimus agreed that the AUC of tacrolimus provides the 
best measure for exposure (32). However, calculation of the AUC requires performing a full 
pharmacokinetic profile which is costly, time consuming and uncomfortable, in particular for 
ambulatory patients. These drawbacks hinder its use in routine practice. A limited sampling 
strategy overcomes the logistical and financial disadvantages of a full pharmacokinetic profile. 
In such a strategy, the AUC is estimated on the basis of a limited number of measurements. 
In chapter 5, we developed a limited sampling strategy for ambulatory patients who use 
prolonged-release tacrolimus. The prediction formula for the AUC0-24 using the time points 0, 2, 
and 4 hours after ingestion (C0h-C2h-C4h) provided a high correlation (r
2) with the AUC0-24  of 0.95. 
The formula (44.9 + 8.9xC0h + 2.1xC2h + 7.6 xC4h) was unbiased and precise.
In daily clinical practice even a limited sampling strategy is cumbersome, and the exposure to 
tacrolimus, for the regular as well as prolonged-release formulation, is commonly estimated 
by measuring the trough level. Trough concentrations of prolonged-release tacrolimus are 
usually measured at 24 hours after taking the drug in the morning. It is impractical to measure 
these trough concentrations in patients who visit the outpatient clinic in the afternoon. Since 
the apparent elimination half-time of prolonged-release tacrolimus is relatively long, we 
hypothesized that  concentrations obtained in the afternoon may also be suitable for estimating 
the 24-hours exposure. In chapter 6, we showed that the concentrations measured at 24, 
26, 28, 30, and 32 hours after the ingestion of prolonged-release tacrolimus were all strongly 
and to an equal extent correlated to AUC0-24h. The collection of a blood sample to measure 
the trough level can therefore be postponed until 32 hours after ingestion for the purpose of 
TDM of prolonged-release tacrolimus. For daily clinical practice, this provides the opportunity 
for ambulatory patients to visit the outpatient clinic, with measurement of the trough level in 
the afternoon. However, adjustment of the target range is required if the concentration at 32 
hours post-dose is used for TDM since there was a significant difference between blood levels 
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obtained at 24 and 32 hours after ingestion. The average concentration at 32 hours post-dose 
was approximately 19% lower than at 24 hours. 
Finally, we investigated the effect of a simplified medication regimen by using prolonged-
release tacrolimus on treatment satisfaction. As described in chapter 7 we conducted a 
prospective cohort study in 75 renal transplant patients. To design a simplified medication 
regimen, the number of drug ingestion times was reduced to one or two convenient time points 
per day, e.g. early in the morning and at bedtime. It permitted patients to remain free of drug 
intake during work or social activities. The introduction of a simplified medication regimen 
increased treatment convenience, which was measured by the validated Treatment Satisfaction 
Questionnaire for Medication (TSQM) version II. Importantly, this regimen also had a beneficial 
effect on self-reported adherence, which changed from 79.7% to 94.6%.
Taken together, the use of prolonged-release tacrolimus has several advantages. It was already 
reported that the intra-patient variability decreased if patients switched from the regular to the 
prolonged-release formulation of tacrolimus (29, 30). Moreover, the efficacy and safety profile 
were comparable to that of the regular formulation after conversion in stable renal transplant 
patients (26, 28). We established that prolonged-release tacrolimus enables to measure trough 
levels also beyond 24 hours and even till 32 hours after the intake. In addition, the exposure to 
tacrolimus can be precisely predicted by a limited sampling strategy, which is also suitable for 
ambulatory patients. Finally, prolonged-release tacrolimus enables to simplify the medication 
regimen which is beneficial for treatment satisfaction and self-reported-adherence. 
However, there are also some notes to be made concerning the use of the prolonged-
release tacrolimus formulation. First, the exposure to tacrolimus decreases by about 15% on 
average after conversion from the regular to the once-daily formulation on a 1:1 mg basis 
(33). Therefore, dose adjustments shortly after conversion are frequently needed to maintain a 
stable exposure in renal transplant patients (34, 35). Particularly, patients expressing CYP3A5 
may require a higher dose after conversion (36). Secondly, the reduction of the intra-patient 
variability is limited and has not been demonstrated consistently and convincingly (29, 30, 
37). Although Stifft et al. showed that the intra-patient variability to tacrolimus decreased, this 
effect was small and clinical relevance can be questioned (29). In another study the effect 
on intra-patient variability was obscured by invalid methods (30). In a recently published 
trial it could not be shown that the conversion reduced the intra-patient variability (37). 
Thirdly, although we showed increased treatment satisfaction and self-reported adherence, 
these outcome measures are not considered to represent hard endpoints in transplantation 
medicine. Likewise, Kuijpers et al. demonstrated in a randomized, multicenter trial that patients 
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who used the prolonged-release formulation had a better adherence and missed less drug 
doses compared to patients with the regular formulation (38). The patients with prolonged-
release tacrolimus also showed more accurate and timely drug intake. Nevertheless, a better 
graft outcome with the use of prolonged-release tacrolimus has never been demonstrated. 
Finally, the price of prolonged-release tacrolimus capsules is higher than that of the regular 
formulation. In an era with emphasis on cost reductions in health services, a valid cost-
effectiveness analysis should be performed to decide whether higher drug expenses are 
justified.
More recently, studies on a novel prolonged-release formulation of tacrolimus (LCPT) have 
been performed (39-41). This novel prolonged-release formulation utilizes a drug delivery 
technology which improves the bioavailability of drugs with low water solubility. The efficacy 
and safety profile of LCPT are comparable with those of the regular formulation of tacrolimus 
(39, 40). The potential added value of this novel prolonged-release formulation compared to 
the available prolonged-release formulation should be sought in a lower daily dose requirement 
and increased flexibility concerning ingestion time of the drug. The equipotent daily dose 
of LCPT is 14-30% lower (depending on CYP3A5 genotype) as compared to the regular 
formulation of tacrolimus due to a higher bioavailability and this might result in lower costs 
(39, 41). Moreover, the pharmacokinetics of LCPT do not depend on circadian rhythm which 
enables to simplify the medication regimen further than with the available prolonged-release 
tacrolimus formulation. Until now, LCPT has only been compared with the regular formulation 
of tacrolimus. A randomized-controlled study comparing both prolonged-release tacrolimus 
formulations is required to establish its added value in transplantation medicine.
Future perspective: personalized immunosuppression
A large array of immunosuppressive agents is available for prevention of rejection in 
recipients of a renal allograft. However, almost every renal transplant patient receives a 
similar combination of immunosuppressive drugs, which includes induction therapy, a 
calcineurin inhibitor, predominantly tacrolimus, MMF and frequently steroids. As most acute 
rejections occur in the first 6 months after renal transplantation, this universal approach 
can be defended for this period in which the focus should be on maximal effectiveness 
of the immunosuppressive therapy (42). However, the maintenance regimen that is used 
beyond the first 6-12 months after transplantation is frequently also a fixed combination 
of immunosuppressive drugs. This fixed combination usually consists of tacrolimus in 
combination with MMF and/or steroids depending on the transplant center and irrespective 
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of the risk of rejection, adverse effects, degree of adherence, original kidney disease, and 
co-morbidity. A fixed regimen in all patients does not take into account the obvious differences 
between patients. In a personalized or tailor made approach, the different factors are balanced 
per individual to optimize the immunosuppressive therapy. We propose to apply this approach 
beyond the first 6-12 months post transplantation. It might improve the efficacy, reduce the 
side effects and increase adherence resulting in better long-term outcomes and a better quality 
of life. 
Immunosuppressive drug trials with the treatment guided by pharmacogenetic traits and TDM 
to individualize immunosuppressive therapy after renal transplantation have been conducted 
(43-45). However, studies in which the choice for an immunosuppressive regimen in a single 
patient is explicitly based on a combination of pharmacogenetics, risk of rejection, adverse 
effects, degree of adherence, original kidney disease, comorbidity, and preference of the 
patient are lacking thus far. We evaluated the available evidence for choosing a specific 
immunosuppressive strategy in an individual with a specified set of clinical characteristics. 
Based on the available data, we developed a preliminary version of a scoring system 
that can aid in choosing the most appropriate maintenance regimen for a given patient. 
Our ultimate goal is to perform a clinical trial in which tailor-made immunosuppression 
according to this scoring system is compared with ‘standard’ therapy. It is a challenge to 
define the most appropriate endpoints for such a trial, trying to find an optimal balance 
between classical endpoints, like graft function and survival, and patient reported outcome 
measures referring to the quality of life. Moreover, motivating renal transplant patients to 
change an immunosuppressive regimen to which they are accustomed can be a difficult job. 
Nevertheless, we feel that such studies will be worthwhile to improve long-term outcome of 
renal transplantation.
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Samenvatting
De afgelopen decennia is de transplantaatoverleving vooral verbeterd dankzij betere resultaten 
in het eerste jaar na niertransplantatie. Het percentage niertransplantatie patiënten dat na 
het eerste jaar het transplantaat verliest, is echter nauwelijks verbeterd en blijft ongeveer 
4% per jaar. In hoofdstuk 1 wordt beschreven dat verschillende immunologische en niet-
immunologische processen het transplantaatverlies op de lange termijn beïnvloeden. In 
dit proefschrift worden onderzoeken beschreven die aangrijpen op de volgende 3 factoren 
die het transplantaatverlies op lange termijn kunnen beïnvloeden: het optimaliseren van de 
immunosuppressieve therapie door het verbeteren van de werkzaamheid, het verminderen 
van de bijwerkingen en het verhogen van de therapietrouw. De nadruk ligt op mycofenolaat 
mofetil en tacrolimus, aangezien dit de meest gebruikte immuunsuppressiva zijn bij 
niertransplantatiepatiënten.
Werkzaamheid en bijwerkingen van immunosuppressiva en de wisselwerking 
met de tractus digestivus
Hoofdstuk 2 omvat een overzicht van de wisselwerking tussen aandoeningen van de tractus 
digestivus en verschillende immunosuppressiva. Gastrointestinale bijwerkingen komen 
veel voor bij gebruik van immunosuppressiva. Deze bijwerkingen beïnvloeden de kwaliteit 
van leven, verminderen de transplantaatoverleving en leiden tot een verhoogde mortaliteit. 
Verder hebben aandoeningen van de tractus digestivus effect op de farmacokinetiek van de 
verschillende immunosuppressiva. De opname van calcineurine remmers, mTOR remmers 
en corticosteroïden wordt beïnvloed door intestinaal cytochroom P450 (CYP3A) en intestinale 
efflux pomp ABCB1. Mycofenolaat wordt gedeeltelijk gemetaboliseerd in de maag en darmen 
en doorloopt een enterohepatische kringloop. Een aandoening van de tractus digestivus 
kan dus de opname beïnvloeden en daarmee de blootstelling aan de immunosuppressiva. 
In het hoofdstuk wordt ook ingegaan op welke wijze de immunosuppressieve therapie kan 
worden aangepast bij deze aandoeningen. Tenslotte wordt aandacht besteed aan de interactie 
tussen immunosuppressiva en medicijnen die vaak worden voorgeschreven in verband met 
aandoeningen van de tractus digestivus.
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Werkzaamheid van mycofenolaat mofetil in combinatie met proton pomp 
remmers
In hoofdstuk 3 beschrijven we een retrospectief onderzoek naar de gevolgen voor het 
percentage histologisch bewezen rejecties in de eerste 3 maanden na niertransplantatie 
bij patiënten die mycofenolaat mofetil gebruiken en gelijktijdig  de protonpomp remmer 
pantoprazol in plaats van de H2 antagonist ranitidine. Proton pomp remmers, die veel gebruikt 
worden als ulcus pepticum profylaxe na niertransplantatie, verminderen immers de blootstelling 
de actieve metaboliet van mycofenolaat mofetil met ongeveer 35%. Er werden 202 patiënten 
geïncludeerd: 125 gebruikten pantoprazol en 77 gebruikten ranitidine. We vonden geen 
significant verschil in percentage histologisch bewezen rejectie tussen beide groepen: 10,4% in 
de pantoprazol groep en 9,1% in de ranitidine groep. Ook na correctie voor verschillen tussen 
beide groepen bleek geen verschil aantoonbaar. We kunnen overigens niet uitsluiten dat in 
bepaalde subgroepen met een verhoogd risico op rejectie zoals bij patiënten van Afrikaanse 
afkomst of na een retransplantatie wel een verschil aanwezig is.
Tacrolimus toxiciteit en milde diarree
Chronische nefrotoxiciteit bij gebruik van tacrolimus of ciclosporine is een van de belangrijkste 
oorzaken van transplantaatverlies. Een verhoogde blootstelling aan deze medicijnen moet 
daarom voorkomen worden. De blootstelling aan tacrolimus is gecorreleerd met de dalspiegel. 
In hoofdstuk 4 beschrijven we ons onderzoek naar de gevolgen van milde diarree op de 
blootstelling aan tacrolimus. Het is bekend dat ernstige diarree (meer dan 3 maal daags 
niet vaste ontlasting) de blootstelling aan tacrolimus substantieel kan verhogen. Van milde 
diarree (2-3 maal daags ontlasting), een veel voorkomende bijwerking van mycofenolaat 
mofetil, is dat onbekend. In ons onderzoek beantwoorden we de vraag of milde diarree 
bij gebruik van mycofenolaat mofetil leidt tot een chronisch verhoogde blootstelling aan 
tacrolimus. We onderzochten ook of milde diarree de intra-individuele variabiliteit in tacrolimus 
blootstelling, een risicofactor voor de transplantaatoverleving, beïnvloedt. In het onderzoek 
participeerden 12 niertransplantatie patiënten die de combinatie van mycofenolaat mofetil 
en tacrolimus gebruikten met milde diarree en 12 patiënten zonder diarree. Beide groepen 
patiënten namen bloed af na inname van tacrolimus met behulp van de ”dried blood spot” 
methode waar op basis van een farmacokinetische curve werd gemaakt. De gemiddelde ratio 
van area under the curve (AUC(0-12)) en dalspiegel was gelijk voor beide groepen: 19,2 (95% 
betrouwbaarheidinterval 17,5-21,1) versus 20,6 (19,0-22,4). Daarmee vonden we dus geen 
bewijs voor chronisch verhoogde blootstelling aan tacrolimus bij patiënten met milde diarree. 
 9
Samenvatting, publicatielijst, curriculum vitae en dankwoord
148
Bovendien bleek de intra-individuele variabiliteit van tacrolimus beperkt te zijn en niet beïnvloed 
te worden door milde diarree.
Tacrolimus met vertraagde afgifte: meten van de blootstelling en  
therapietevredenheid
Tacrolimus is aanvankelijk ontwikkeld als een medicijn dat tweemaal daags ingenomen moet 
worden. In 2007 is een vorm met gereguleerde afgifte geïntroduceerd die slechts een keer per 
dag kon worden ingenomen. De werkzaamheid van tacrolimus met gereguleerde afgifte is 
vergelijkbaar en de bijwerkingen verschillen niet. In de hoofdstukken 5 en 6 beschrijven wij 
onderzoeken die de blootstelling aan tacrolimus met gereguleerde afgifte meten. In hoofdstuk 
7 richten we ons op het gevolg van een vereenvoudigd medicatie innameschema bij gebruik 
van tacrolimus met gereguleerde afgifte op de therapie tevredenheid.
Controle van tacrolimus dalspiegels is geïndiceerd om een verhoogde blootstelling aan 
het medicijn te voorkomen en de intra-patient variabiliteit te verlagen. Een consortium van 
Europese experts stelde vast dat de AUC de beste maat voor blootstelling aan tacrolimus is. 
Echter het maken van een volledige farmacokinetische curve is kostbaar, vergt veel tijd en is 
onhandig voor vooral poliklinische patiënten. Daarom wordt het nauwelijks toegepast in de 
klinische praktijk en wordt veel gebruik gemaakt van dalspiegels. Een limited sampling strategy 
komt tegemoet aan een aantal van deze bezwaren. Hierbij wordt de AUC geschat op basis 
van een beperkt aantal metingen. In hoofdstuk 5 beschrijven we de ontwikkeling van een 
limited sampling strategy voor poliklinische patiënten die tacrolimus met gereguleerde afgifte 
gebruiken. De formule met meetpunten op 0,2 en 4 uur na inname had de hoogste correlatie 
met de AUC (r2 = 0,95). Deze formule (44,9 + 8,9 x C0 + 2,1 x C2 + 7,6 x C4) was zonder bias 
en precies.
In de dagelijkse klinische praktijk blijkt een limited sampling strategy niet altijd haalbaar en 
daarom wordt veel gebruik gemaakt van dalspiegels. De dalspiegels van tacrolimus met 
gereguleerde afgifte worden meestal in de ochtend 24 uur na inname afgenomen. Voor 
patiënten die in de middag de polikliniek bezoeken is dit erg onhandig. Het onderzoek dat we 
in hoofdstuk 6 beschrijven gaat over de vraag of de dalspiegel meer dan 24 uur na inname 
ook nog een goede voorspeller is van de blootstelling aan tacrolimus. We laten zien dat 
dalspiegels gemeten op 24, 26, 28, 30 en 32 uur na inname allen even sterk correleren met de 
blootstelling. Dit geeft patiënten die in de middag de polikliniek bezoeken ook de mogelijkheid 
tot 32 uur na inname van tacrolimus bloed voor een dalspiegel te laten afnemen. Andere 
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referentiewaarden voor de dalspiegel zijn dan nodig omdat de gemiddelde dalspiegel 32 uur 
na inname ongeveer 19% lager is dan 24 uur na inname.
Tenslotte onderzochten we het effect van een vereenvoudig medicatieregime bij gebruik 
van tacrolimus met gereguleerde afgifte op de therapietevredenheid. In hoofdstuk 7 
beschrijven we een prospectief cohort van 75 niertransplantatie patiënten. Een vereenvoudigd 
medicatieregime betekende dat het maximale aantal inname momenten werd beperkt tot 
maximaal 2 gemakkelijke tijdstippen, bijvoorbeeld vroeg in de ochtend en voor het slapen. 
Daardoor hoefden patiënten bijvoorbeeld niet tijdens hun werk of bij sociale activiteiten hun 
medicijnen in te nemen. De introductie van een vereenvoudigd medicatieregime verhoogde 
het therapiegemak, dat gemeten werd met een gevalideerde vragenlijst Treatment Satisfaction 
Questionnaire for Medication (TSQM) versie II. Ook had dit vereenvoudigde medicatieregime 
een gunstig effect op de door henzelf gerapporteerde therapietrouw die toenam van 79,7% 
naar 94,6%.
In hoofdstuk 8 volgt tenslotte de samenvatting van het proefschrift en plaatsen we het 
verrichte onderzoek in een bredere context. Thans krijgt elke niertransplantatie patiënt 
ongeacht het risico op rejectie, ervaren bijwerkingen, mate van therapietrouw, nefrologisch 
grondlijden en comorbiditeit vrijwel hetzelfde immunosuppressieve regime na de eerste 6-12 
maanden. Wij hebben de hypothese dat door invoering van immunosuppressieve therapie 
afgestemd op het individu de werkzaamheid verbetert, het aantal bijwerkingen vermindert, de 
therapietrouw verhoogt en daarmee zal resulteren betere lange termijn uitkomsten en kwaliteit 
van leven na niertransplantatie. 
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